UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

SCHEDULE 14A

___________________

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Under §240.14a-12

Cepton, Inc.


(Name of Registrant as Specified In Its Charter)

Not applicable

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

Table of Contents

CEPTON, INC.
399 West Trimble Road
San Jose, California 95131
(408) 459-7579

August 8, 2023

Dear Stockholder,

You are cordially invited to attend a special meeting of stockholders of Cepton, Inc., a Delaware corporation (the “Company”), which will be held on September 7, 2023, at 9:00 a.m. Pacific Time, conducted solely online via live webcast (the “Special Meeting”). We believe hosting a virtual meeting enables increased stockholder attendance and participation from locations around the world. Stockholders attending the virtual meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting. You will be able to attend and participate in the Special Meeting online, vote your shares electronically and submit your questions prior to the meeting at https://www.cstproxy.com/cepton/sm2023 and during the meeting by visiting https://www.cstproxy.com/cepton/sm2023 at the meeting date and time described in the accompanying Proxy Statement. The conference ID for the meeting is 3127195#. There is no physical location for the Special Meeting.

Please use this opportunity to take part in the affairs of our company by voting on the business to come before this Special Meeting. Whether or not you plan to attend the virtual Special Meeting, please sign, date and return the accompanying proxy card or voting instruction form in the postage-paid envelope provided or submit your proxy or voting instructions electronically via the Internet or by telephone. See “Questions and answers about the proxy materials and Special Meeting — How do I vote and what are the voting deadlines?” in the Proxy Statement for more details. You may also vote your shares online during the Special Meeting. Instructions for each type of voting are included on your proxy card or voting instruction form. Returning the proxy card or voting instruction form or submitting your proxy or voting instructions electronically does not deprive you of your right to attend the virtual Special Meeting and to vote your shares online during the virtual Special Meeting.

NOTICE OF ANNUAL MEETING OF
STOCKHOLDER
SBy Order of the Board of Directors

Jun Pei

President and Chief Executive Officer

August 8, 2023

Table of Contents

NOTICE OF SPECIAL MEETING OF
STOCKHOLDERS

Thursday, May 18,September 7, 2023
9:00 a.m. Pacific Time

How to
Participate:HOW TO PARTICIPATE:

 

Our annual meetingSpecial Meeting will be a completely virtual meeting of stockholders. To participate, vote or submit questions during the annual meetingSpecial Meeting via live webcast, please visit: https://www.cstproxy.com/cepton/am2023.sm2023. You will not be able to attend the annual meetingSpecial Meeting in person.

Items of
Business:ITEMS OF BUSINESS:

 

(1)    Proposal OneElect

Approve a series of sixteen alternative potential amendments to the three Class A directors namedCompany’s Second Amended and Restated Certificate of Incorporation to authorize the Company’s Board of Directors to effect (i) a reverse stock split of the issued shares of our common stock (including shares of common stock held by the Company in treasury), at ratios of 1 share of common stock for each whole number of issued shares of our common stock between five and twenty, which ratio to become effective to be determined by the Board of Directors if the Board of Directors subsequently determines to proceed with the reverse stock split, and (ii) a corresponding reduction in the accompanying Proxy Statementtotal number of authorized shares of common stock and corresponding reduction in the total number of shares the Company is authorized to serve until the Company’s 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified;issue;

  

(2)    Proposal TwoRatify

Adjourn the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023;Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve Proposal One; and

  

(3)    Transact such other business as may properly come before the meeting, or any postponements or adjournments thereof.

Who May Vote:WHO MAY VOTE:

 

Stockholders of record atof our common stock as of the close of business on March 20,July 28, 2023.

stockholder
list:STOCKHOLDER LIST:

 

A complete list of stockholders of record of our common stock entitled to vote at the annual meetingSpecial Meeting will be maintained in our principal executive offices at 399 West Trimble Road, San Jose, California 95131 for ten days prior to the annual meeting.Special Meeting.

Your vote is important to us. Whether or not you expect to attend the annual meetingSpecial Meeting via live webcast, please submit a proxy or voting instructions as soon as possible to instruct how your shares are to be voted at the annual meeting.Special Meeting. If you participate in and vote your shares at the annual meeting,Special Meeting, your proxy will not be used.

i

Table of Contents

Table of Contents

 

By Order of the Board of Directors,

Dr. Jun PeiPage

President and Chief Executive Officer
April 6, 2023

TABLE OF CONTENTS

Page

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

Important Notice Regarding Proxy Materialsnotice of special meeting of stockholders

i

IMPORTANT NOTICE REGARDING PROXY MATERIALS

 

1

Meeting InformationMEETING INFORMATION

 

2

Proposal 1 PROPOSAL ONE — Election of DirectorsAPPROVAL OF A REVERSE STOCK SPLIT OF Our Issued COMMON STOCK AND A CORRESPONDING REDUCTION IN THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK

 

3

Corporate GovernancePROPOSAL TWO — VOTE ON ADJOURNMENT

 

714

Director Compensation

15

Executive Officers of the CompanyOTHER MATTERS

 

17

Executive CompensationQUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND Special MEETING

 

18

Summary Compensation TableAPPENDIX A — Fiscal Years 2021-2022CERTIFICATE OF AMENDMENT OF SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CEPTON, INC

 

18

Outstanding Equity Awards as of December 31, 2022

19

2022 Equity Grants

20

Non-Equity Incentive Plan Compensation

20

Executive Employment and Severance Agreements

20

Defined Contribution Plans

21

Compensation Committee Interlocks and Insider Participation

22

Security Ownership of Certain Beneficial Owners and Management

22

Equity Incentive Plan Information

24

Report of Audit Committee

25

Proposal 2 — Ratification of Independent Registered Public Accounting Firm

26

Transactions with Related Persons

27

Delinquent Section 16(a) Reports

30

Proposals of Stockholders and Director Nominations for 2024 Annual Meeting

31

Other Matters

32

Annual Report to Stockholders

32

Questions and Answers About the Proxy Materials and Annual Meeting

33A-1

ii

Table of Contents

PROXY STATEMENT

399 West Trimble Road
San Jose, California 95131

PROXY STATEMENT

AnnualSpecial Meeting of Stockholders
To Be Held May 18,September 7, 2023

OurThese proxy materials are being furnished to you in connection with the solicitation of proxies by the Board of Directors is soliciting your proxy(the “Board”) of Cepton, Inc. for use at the 2023 AnnualSpecial Meeting of Stockholders (the “Annual Meeting”Special Meeting) to be held on Thursday, May 18,September 7, 2023 at 9:00 a.m. Pacific Time, and at any and all postponements or adjournments of the AnnualSpecial Meeting, for the purposes set forth in the Notice of AnnualSpecial Meeting of Stockholders accompanying this Proxy Statement. This Proxy Statement and proxy materials are first being made available to stockholders on or about April 6,August 8, 2023.

We will be hosting the AnnualSpecial Meeting via live webcast on the Internet. Any stockholder can listen to and participate in the AnnualSpecial Meeting live via the Internet at https://www.cstproxy.com/cepton/am2023.sm2023. Stockholders may vote and ask questions while connected to the AnnualSpecial Meeting on the Internet.

You will not be able to attend the AnnualSpecial Meeting in person.

Unless the context otherwise requires, references in this Proxy Statement to “Company,” “we,” “our,” “us,” and similar terms refer to Cepton, Inc., a Delaware corporation. Our company website can be found at www.cepton.com. Our common stock is traded on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CPTN”. Information contained on or accessible through Cepton’s website is not a part of this Proxy Statement.

IMPORTANT NOTICE REGARDING PROXY MATERIALS

In accordance with rules and regulations adopted by the U.S. Securities and Exchange Commission (“SEC”SEC), we have elected to provide access to our proxy materials by sending you this full set of proxy materials, including a proxy card. Accordingly, the Proxy Statement and accompanying proxy card will first be mailed to our stockholders on or about April 6,August 8, 2023. Our proxy materials are also available to our stockholders free of charge at https://investors.cepton.cominvestors.cepton.com.

CEPTON, INC.

2023 PROXY STATEMENT

1

1

Table of Contents

MEETING INFORMATION

AnnualSpecial Meeting of Stockholders

TIME AND DATE

 

PLACE

 

RECORD DATE

9:00 a.m. Pacific Time
onSeptember Thursday, May 18,7, 2023

 

The AnnualSpecial Meeting will be hosted
via live webcast on the Internet at
https://www.cstproxy.com/cepton/am2023.sm2023.

 

March 20,July28, 2023

Voting

Stockholders as of the close of business on the record date are entitled to vote.

Vote by Internet at
www.cstproxyvote.com

Vote during the meeting via the Internet at https://www.cstproxy.com/cepton/am2023.sm2023.

Voting Matters

PROPOSALS

   

BOARD
RECOMMENDATION

1One

 

ElectionApprove a series of sixteen alternative potential amendments to the Company’s Second Amended and Restated Certificate of Incorporation to authorize the Company’s Board of Directors to effect (i) a reverse stock split of the issued shares of our common stock (including shares of common stock held by the Company in treasury), at ratios of 1 share of common stock for each whole number of issued shares of our common stock between five and twenty, which ratio to become effective to be determined by the Board of Directors if the Board of Directors subsequently determines to proceed with the reverse stock split, and (ii) a corresponding reduction in the total number of authorized shares of common stock and corresponding reduction in the total number of shares the Company is authorized to issue.

FOR

Two

 

FOR ALL
director nominees

2Adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve Proposal One.

 

Ratification of the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Year Ending December 31, 2023.

FOR

2

2023 PROXY STATEMENT

CEPTON, INC.

2

Table of Contents

PROPOSAL ONE — APPROVAL OF A REVERSE STOCK SPLIT OF Our Issued COMMON STOCK AND A CORRESPONDING REDUCTION IN THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK

We are asking stockholders to approve a series of sixteen alternative potential amendments (each a “Split Amendment” and collectively, the “Split Amendments”) to our Second Amended and Restated Certificate of Incorporation to authorize the Board to implement (i) a reverse stock split of the issued shares of our common stock (including shares of common stock held by the Company in treasury) at ratios of 1 share of common stock for each whole number of issued shares of our common stock between five and twenty, which ratio to become effective to be determined by the Board if the Board subsequently determines to proceed with the reverse stock split (the “Reverse Stock Split”) and (ii) a corresponding reduction in the total number of authorized shares of common stock and a corresponding reduction in the total number of shares the Company is authorized to issue as set forth under “Relationship Between the Reverse Stock Split Ratio and the Authorized Shares Reduction” below (the “Authorized Shares Reduction”). The Board has unanimously approved and declared advisable each of the Split Amendments to implement the Reverse Stock Split and the Authorized Shares Reduction and recommends that our stockholders approve each of the Split Amendments to effect this Proposal One. For convenience of our stockholders, each of the Split Amendments has been set forth in a single Certificate of Amendment attached hereto as Appendix A (the “Certificate of Amendment”), indicating in brackets the Reverse Stock Split ratio and the corresponding total number of authorized shares and number of authorized shares of Common Stock that we would be authorized to issue for each of the alternate Split Amendments. The Board will determine which of the Split Amendments, if any, will become effective. Only one Split Amendment will be filed with the Secretary of State of the State of Delaware and therefore only one Split Amendment can become effective. All other Split Amendments will automatically be abandoned. The Board may also decide not to effect any of the Split Amendments, in which case all of the Split Amendments will be abandoned.

If stockholders approve this Proposal One, the stockholders will have approved a series of sixteen separate amendments to our Second Amended and Restated Certificate of Incorporation authorizing (i) the Reverse Stock Splits, pursuant to which each whole number of our issued shares of common stock between five and twenty will be combined into one share of our common stock and (ii) the reduction in the number of authorized shares of our common stock and the number of shares the Company is authorized to issue. The Company is currently authorized to issue 355,000,000 shares consisting of 350,000,000 shares of our common stock and 5,000,000 shares of our preferred stock. The table below represents each of the Split Amendments the stockholders are being asked to approve (each amendment representing a ratio of one to each whole number between five and twenty, designated as Amendments A-P) and sets forth each possible Reverse Stock Split ratio and the corresponding reduction in the total number of authorized shares of common stock and the total authorized number of shares that would be effected with respect to each such Split Amendment. The number of authorized shares of our preferred stock will remain at 5,000,000 irrespective of which, if any, of the proposed amendments become effective.

Relationship Between the Reverse Stock Split Ratio and the Authorized Shares Reduction

Amendments

 

Reverse Stock 
Split Ratio 
Range

 

Number of Authorized 
Shares of Common 
Stock Following the 
Reverse Stock Split and 
Authorized 
Shares Reduction

 

Total Number of 
Authorized Shares of 
Stock Following the 
Reverse Stock Split 
and Authorized Shares 
Reduction

A

 

1-for-5

 

70,000,000

 

75,000,000

B

 

1-for-6

 

60,000,000

 

65,000,000

C

 

1-for-7

 

50,000,000

 

55,000,000

D

 

1-for-8

 

45,000,000

 

50,000,000

E

 

1-for-9

 

40,000,000

 

45,000,000

F-G

 

1-for-10 to 1-for-11

 

35,000,000

 

40,000,000

H-I

 

1-for-12 to 1-for-13

 

30,000,000

 

35,000,000

J-K

 

1-for-14 to 1-for-15

 

25,000,000

 

30,000,000

L-M

 

1-for-16 to 1-for-17

 

22,500,000

 

27,500,000

N-O

 

1-for-18 to 1-for-19

 

20,000,000

 

25,000,000

P

 

1-for-20

 

17,500,000

 

22,500,000

3

Table of Contents

If the stockholders approve Proposal One, the Board will have the authority, but not the obligation, in its sole discretion, at any time prior to the one year anniversary of the Special Meeting, to elect without further action on the part of the stockholders, as it determines to be in the best interests of the Company and its stockholders, whether to effect a Reverse Stock Split and Authorized Shares Reduction and, if so, to determine the Reverse Stock Split ratio and corresponding reduction to the number of authorized shares to effectuate by choosing which of the approved Split Amendments set forth above shall become effective. To effect the Split Amendment chosen by the Board, the Company will file with the Secretary of State the Certificate of Amendment reflecting the Reverse Stock Split ratio and authorized number of shares chosen by the Board. The Authorized Shares Reduction is not directly proportional to the Reverse Stock Split ratio, which means, in the event the Reverse Stock Split is implemented, there may be an effective increase in the number of authorized shares of common stock available for issuance. No further action on the part of stockholders will be required to either implement or abandon the Reverse Stock Split and Authorized Shares Reduction.

We are proposing that the Board have the discretion to select a Reverse Stock Split ratio between one-for-five (1:5) to one-for-twenty (1:20), rather than proposing that stockholders approve one specific ratio at this time, in order to give the Board the flexibility to implement a Reverse Stock Split at a ratio that reflects the Board’s then-current assessment of the factors described below under “Criteria to be Used for Determining Whether to Implement Reverse Stock Split.” We believe that enabling the Board to determine which ratio of the Reverse Stock Split within the stated range is in the best interests of the Company’s stockholders because it will provide us with the flexibility to implement the Reverse Stock Split in a manner designed to maximize the anticipated benefits for the Company and its stockholders and because it is not possible to predict market conditions at the time the Reverse Stock Split would be implemented.

As of June 30, 2023, there were 158,224,189 shares of common stock issued and 158,224,189 shares of common stock outstanding. Based on such number of shares of common stock issued, immediately following the effectiveness of the Reverse Stock Split (and without giving any effect to the payment of cash in lieu of fractional shares), we will have, depending on the Reverse Stock Split ratio selected by the Board, issued shares of stock as illustrated in the table under the caption “— Principal Effects of the Reverse Stock Split and the Authorized Shares Reduction — Effect on Shares.”

All holders of common stock will be affected proportionately by the Reverse Stock Split, except to the extent that the Reverse Stock Split results in the payment of cash to any stockholder in lieu of issuing a fractional share.

No fractional shares of common stock will be issued as a result of the Reverse Stock Split. Instead, any stockholders who would have been entitled to receive a fractional share as a result of the Reverse Stock Split will receive cash payments in lieu of such fractional shares (see “— Fractional Shares”). The transfer agent will aggregate all fractional shares and sell them as soon as practicable after the effective date at the then-prevailing prices on the open market. Stockholders who would otherwise be entitled to receive a fractional share as a result of the Reverse Stock Split will receive a cash payment from the transfer agent in an amount equal to their respective pro rata share of the total proceeds of that sale net of any brokerage and other costs incurred by the transfer agent to sell such stock. While the effect of the Reverse Stock Split will be to reduce the number of issued shares, each holder of common stock will hold the same percentage of the issued shares of common stock immediately following the Reverse Stock Split as that stockholder did immediately prior to the Reverse Stock Split, except to the extent that the Reverse Stock Split results in stockholders receiving cash in lieu of fractional shares. The par value of our common stock will continue to be $0.00001 per share (see “— Principal Effects of the Reverse Stock Split and the Authorized Shares Reduction — Effect of Reverse Stock Split on Stated Capital”).

Background and Reasons for the Reverse Stock Split

The Board believes that, should the appropriate circumstances arise, effecting the Reverse Stock Split would, among other things, help us to:

•        increase the per-share price of our common stock;

•        maintain the listing of our common stock on Nasdaq; and

•        potentially improve the marketability and liquidity of our common stock.

4

Table of Contents

Increase the Per-Share Price of our Common Stock

The primary purpose for effecting the Reverse Stock Split, should the Board choose to effect it, would be to increase the per share price of our common stock. In determining to seek authorization for this Proposal One, the Board considered that, by combining a number of pre-split shares into one share of common stock, the market price of a post-split share is generally greater than the market price of a pre-split share. However, we cannot assure you that the Reverse Stock Split will increase the per share price of our common stock or that any such increase will be proportional to the Reverse Stock Split ratio (see “Certain Risks and Potential Disadvantages Associated with the Reverse Stock Split and the Authorized Shares Reduction”).

Maintain Listing on Nasdaq

Our common stock is listed on Nasdaq under the symbol “CPTN.” On April 13, 2023, we were notified by Nasdaq that we were no longer in compliance with the continued listing requirements of Nasdaq because the average trading price of our common stock over a 30 consecutive business day period had fallen below $1.00 per share, which is the minimum bid price per share required to maintain listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2). Even if the market price per share of our common stock post-Reverse Stock Split is in excess of $1.00 per share, we may be delisted in the future if we fail to meet Nasdaq’s continued listing requirements.

Potentially Improve the Marketability and Liquidity of our Common Stock

The Board believes that continued listing on Nasdaq provides overall credibility to an investment in our common stock, given the stringent listing and disclosure requirements of Nasdaq. In addition, the Board believes that the increased market price of our common stock expected as a result of implementing a Reverse Stock Split could improve the marketability and liquidity of our common stock and encourage interest and trading in our common stock by mitigating the negative effects of certain practices and policies:

•        Stock Price Requirements:    Many brokerage firms have internal policies and practices that have the effect of discouraging individual brokers from recommending lower-priced securities to their clients. Many institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios, which reduces the number of potential purchasers of our common stock. Investment funds may also be reluctant to invest in lower-priced stocks.

•        Stock Price Volatility:    A higher stock price may increase the acceptability of our common stock to a number of long-term investors who may not find our common stock attractive at its current prices due to the trading volatility often associated with stocks below certain prices. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower-priced stocks.

•        Transaction Costs:    Investors may be dissuaded from purchasing stocks below certain prices because brokers’ commissions, as a percentage of the total transaction value, can be higher for lower-priced stocks.

•        Access to Capital Markets:    If our common stock is delisted from Nasdaq, investor demand for additional shares of our common stock could be limited, thereby preventing us from accessing the public equity markets.

We believe that the Reverse Stock Split, if effected, could increase analyst and broker interest in our common stock by avoiding these policies and practices. Increasing visibility of our common stock among a larger pool of potential investors could result in higher trading volumes. We also believe that the Reverse Stock Split may make our common stock a more attractive and cost-effective investment for many investors, which could enhance the liquidity of our common stock for our stockholders. These increases in visibility and liquidity could also help facilitate future financings and give management more flexibility to focus on executing our business strategy, which includes the strategic management of authorized capital for business purposes.

Accordingly, for these and other reasons discussed herein, we believe that being able to effect the Reverse Stock Split is in the best interests of the Company and its stockholders.

5

Table of Contents

Reasons for the Authorized Shares Reduction

As a matter of Delaware law, the implementation of a reverse stock split does not require a reduction in the total number of authorized shares of common stock. However, without the Authorized Shares Reduction, the Reverse Stock Split would significantly increase the proportion of unissued, authorized shares of common stock that could be issued, which could allow the Company to dilute stockholders more in the future than it is currently able to do. The Board believes that effecting the Authorized Shares Reduction in connection with the Reverse Stock Split will maintain alignment with the market expectations regarding the number of shares of authorized common stock in comparison to the number of shares issued or reserved for issuance, and ensure that we do not have what some stockholders might view as an unreasonably high number of authorized shares of common stock that are unissued or reserved for issuance following the Reverse Stock Split.

The Authorized Shares Reduction is not directly proportional to the Reverse Stock Split ratio, which means, in the event the Reverse Stock Split is implemented, there may be an effective increase in the number of authorized shares of common stock available for issuance. However, this increase, if any, will be substantially smaller than the effect a Reverse Stock Split would have had without an Authorized Share Reduction.

Criteria to be Used for Determining Whether to Implement the Reverse Stock Split

In determining whether and when to effect the Reverse Stock Split and which Reverse Stock Split ratio to implement, if any, following receipt of stockholder approval of this Proposal One, the Board may consider, among other things, various factors, such as:

•        the historical trading price and trading volume of our common stock;

•        the then-prevailing trading price and trading volume of our common stock and the expected impact of the Reverse Stock Split on the trading market for our common stock in the short- and long-term;

•        the continued listing requirements for our common stock on Nasdaq or other applicable exchange;

•        actual and forecasted results of operations, and the likely effect of such results on the market price of our common stock;

•        the projected impact of the Reverse Stock Split ratio on trading liquidity in our common stock;

•        the number of shares of common stock issued;

•        the anticipated impact of a particular Reverse Stock Split ratio on our ability to reduce administrative and transactional costs; and

•        prevailing general market, industry and economic conditions.

Certain Risks and Potential Disadvantages Associated with the Reverse Stock Split and the Authorized Shares Reduction

We cannot assure you that the proposed Reverse Stock Split will increase the price of our common stock.    We expect that the Reverse Stock Split will increase the market price of our common stock. However, the effect of the Reverse Stock Split on the market price of our common stock cannot be predicted with any certainty, and the history of reverse stock splits for other companies is varied, particularly since some investors may view a reverse stock split negatively. It is possible that the per-share price of our common stock after the Reverse Stock Split will not increase in the same proportion as the reduction in the number of issued shares of common stock following the Reverse Stock Split, and the Reverse Stock Split may not result in a per-share price that would attract investors who do not trade in lower-priced stocks. In addition, although we believe that the Reverse Stock Split may enhance the marketability of our common stock to certain potential investors, we cannot assure you that, if implemented, our common stock will be more attractive to investors. Even if we implement the Reverse Stock Split, the market price of our common stock may decrease due to factors unrelated to the Reverse Stock Split, including our future performance. If the Reverse

6

Table of Contents

Stock Split is consummated and the trading price of our common stock declines, the percentage decline as an absolute number and as a percentage of our overall market capitalization may be greater than would occur in the absence of the Reverse Stock Split.

We may not satisfy the Nasdaq continued listing requirements following the Reverse Stock Split.    While we intend to monitor the average closing price of our common stock and consider available options if it does not continue to trade at a level likely to result in us maintaining compliance, no assurances can be made that we will in fact be able to comply and that our common stock will remain listed on Nasdaq. If our common stock ultimately were to be delisted from Nasdaq for any reason, it could negatively impact us as it would likely reduce the liquidity and market price of our common stock; reduce the number of investors willing to hold or acquire our common stock; negatively impact our ability to access equity markets, issue additional securities and obtain additional financing in the future; affect our ability to provide equity incentives to our employees; and might negatively impact our reputation and, as a consequence, our business.

The proposed Reverse Stock Split may decrease the liquidity of our common stock and result in higher transaction costs.    The liquidity of our common stock may be negatively impacted by the Reverse Stock Split, given the reduced number of shares that would be outstanding after the Reverse Stock Split, particularly if the stock price does not increase as a result of the Reverse Stock Split. In addition, if the Reverse Stock Split is implemented, it may increase the number of our stockholders who own “odd lots” of fewer than 100 shares of common stock, which may be more difficult to sell. Brokerage commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares or of even multiples of 100 shares of common stock. Accordingly, the Reverse Stock Split may not achieve the desired results of increasing marketability of our common stock as described above.

Effective Time

The effective time of the Split Amendment (the “Effective Time”), if approved by stockholders and implemented by us, will be the date and time the Certificate of Amendment is filed with the Delaware Secretary of State, or such later time set forth therein. See below under “Reservation of Right to Delay the Filing of the Certificate of Amendment, or Abandon the Reverse Stock Split and the Authorized Shares Reduction.”

Except as to fractional shares, at the Effective Time, the Reverse Stock Split will combine, automatically and without any action on the part of us or our stockholders, the shares of common stock issued (including shares of common stock held by the Company in treasury) immediately prior thereto into a lesser number of new shares of common stock in accordance with the Reverse Stock Split ratio determined by the Board within the limits set forth in this Proposal One and as reflected in the Split Amendment filed with Delaware Secretary of State. Also at the Effective Time, the Authorized Shares Reduction will reduce, automatically and without any action on the part of us or our stockholders, the number of authorized shares of common stock and total number of authorized shares as reflected in the Split Amendment filed with the Delaware Secretary of State.

Fractional Shares

Stockholders will not receive fractional shares of common stock in connection with the Reverse Stock Split. Instead, the transfer agent will aggregate all fractional shares and sell them as soon as practicable after the Effective Time at the then-prevailing prices on the open market, on behalf of those stockholders who would otherwise be entitled to receive a fractional share as a result of the Reverse Stock Split. We expect that the transfer agent will conduct the sale in an orderly fashion at a reasonable price and that it may take several days to sell all of the aggregated fractional shares of common stock. After the transfer agent’s completion of such sale, stockholders who would have been entitled to a fractional share will instead receive a cash payment from the transfer agent in an amount equal to their respective pro rata share of the total proceeds of that sale net of any brokerage and other costs incurred by the transfer agent to sell such stock. After the Effective Time, a stockholder otherwise entitled to a fractional interest will not have any voting, dividend or other rights with respect to such fractional interest, except to receive payment as described herein.

7

Table of Contents

Stockholders will not be entitled to receive interest for the period of time between the Effective Time and the date payment is made for their fractional share interest. You should also be aware that, under the escheat laws of certain jurisdictions, sums due for fractional interests that are not timely claimed after the funds are made available may be required to be paid to the designated agent for each such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds may have to obtain the funds directly from the state to which they were paid.

If you believe that you may not hold sufficient shares of common stock at the Effective Time to receive at least one share in the Reverse Stock Split and you want to continue to hold common stock after the Reverse Stock Split, you may do so by either:

•        purchasing a sufficient number of shares of common stock; or

•        if you have shares of common stock in more than one account, consolidating your accounts;

in each case, so that you hold a number of shares of common stock in your account prior to the Reverse Stock Split that would entitle you to receive at least one share of common stock in the Reverse Stock Split. Shares of common stock held in registered form and shares of common stock held in “street name” (that is, through a broker, bank or other holder of record) for the same stockholder will be considered held in separate accounts and will not be aggregated when effecting the Reverse Stock Split.

Principal Effects of the Reverse Stock Split and the Authorized Shares Reduction

General

After the Effective Time, the number of our issued shares of common stock will decrease at the Reverse Stock Split ratio of not less than one-for-five (1:5) and not more than one-for-twenty (1:20). The Reverse Stock Split would be effected simultaneously for all of our issued common stock (including shares of common stock held by the Company in treasury), and the exchange ratio will be the same for all shares of issued common stock (including shares of common stock held by the Company in treasury) and each stockholder will own a reduced number of shares of common stock. The Reverse Stock Split will affect all of our stockholders uniformly and will not affect any stockholder’s percentage ownership interests in the Company, except to the extent that the Reverse Stock Split results in any of our stockholders receiving cash in lieu of fractional share as described above. Voting rights and other rights and preferences of the holders of common stock will not be affected by the Reverse Stock Split (other than as a result of the payment of cash in lieu of fractional shares). For example, a holder of 2% of the voting power of the issued shares of common stock immediately prior to the Reverse Stock Split would continue to hold 2% (assuming there is no impact as a result of the payment of cash in lieu of issuing fractional shares) of the voting power of the issued shares of common stock immediately after the Reverse Stock Split. The number of stockholders of record will not be affected by the Reverse Stock Split (except to the extent that any stockholder holds only a fractional share interest and receives cash for such interest after such Reverse Stock Split). The Reverse Stock Split would not affect our securities law reporting and disclosure obligations, and we would continue to be subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

The principal effects of the Reverse Stock Split and the Authorized Shares Reduction will be that:

•        each five to twenty whole shares of common stock owned by a stockholder (depending on the Reverse Stock Split ratio selected by the Board), will be combined into one new share of common stock;

•        no fractional shares of common stock will be issued in connection with the Reverse Stock Split; instead, holders of common stock who would otherwise receive a fractional share of common stock pursuant to the Reverse Stock Split will receive cash in lieu of the fractional share as explained above;

•        the authorized number of shares of common stock and the total number of authorized shares of all classes of stock will be reduced in the amount corresponding with the Reverse Stock Split ratio as set forth under “Relationship Between the Reverse Stock Split Ratio and the Authorized Shares Reduction” above;

•        based upon the Reverse Stock Split ratio selected by the Board, adjustments will be made to all then-outstanding awards under all of the Company’s equity plans, the per-share exercise price and the number of shares issuable upon the exercise of the Warrants and to the per-share conversion price and

8

Table of Contents

the number of shares issuable upon conversion of the Company’s Series A Convertible Preferred Stock in accordance with the provisions of the Company’s equity plans, the Warrants and the Company’s Series A Convertible Preferred Stock, respectively;

•        the number of stockholders owning “odd lots” of less than 100 shares of common stock may potentially increase and, although odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots generally are proportionately higher than the costs of transactions in “round lots” of even multiples of 100 shares, we believe, however, that these potential negative effects are outweighed by the benefits of the Reverse Stock Split; and

•        the number of shares then reserved for issuance under the Company’s equity plans, the Warrants and the Company’s Series A Convertible Preferred Stock will be reduced in in accordance with the provisions of the Company’s equity plans, the Warrants and the Company’s Series A Convertible Preferred Stock, respectively, based on the Reverse Stock Split ratio.

Effect on Shares

The following table contains approximate information, based on share information as of June 30, 2023, relating to the issued shares of common stock based on selected proposed Reverse Stock Split ratios and information regarding our shares of common stock authorized but not issued or reserved for issuance that will remain available for issuance immediately following the effectiveness of such Reverse Stock Split and the corresponding Authorized Shares Reduction (assuming that this Proposal One is approved and implemented):

Status

 

Number of 
Shares of 
Common Stock 
Authorized

 

Number of 
Shares of 
Common Stock 
Issued

 

Number of 
Shares of 
Common Stock 
Reserved 
for Future 
Issuance
(1)

 

Number of 
Shares of 
Common Stock 
Authorized but 
Not Issued or 
Reserved

Pre-Reverse Stock Split and Authorized Shares Reduction

 

350,000,000

 

158,224,189

 

119,603,121

 

72,172,690

Post-Reverse Stock Split and Authorized Shares Reduction 1:5

 

70,000,000

 

31,644,837

 

23,920,624

 

14,434,539

Post-Reverse Stock Split and Authorized Shares Reduction 1:6

 

60,000,000

 

26,370,698

 

19,933,853

 

13,695,449

Post-Reverse Stock Split and Authorized Shares Reduction 1:7

 

50,000,000

 

22,603,455

 

17,086,160

 

10,310,385

Post-Reverse Stock Split and Authorized Shares Reduction 1:8

 

45,000,000

 

19,778,023

 

14,950,390

 

10,271,587

Post-Reverse Stock Split and Authorized Shares Reduction 1:9

 

40,000,000

 

17,580,465

 

13,289,235

 

9,130,300

Post-Reverse Stock Split and Authorized Shares Reduction 1:10

 

35,000,000

 

15,822,418

 

11,960,312

 

7,217,270

Post-Reverse Stock Split and Authorized Shares Reduction 1:12

 

30,000,000

 

13,185,349

 

9,966,926

 

6,847,725

Post-Reverse Stock Split and Authorized Shares Reduction 1:14

 

25,000,000

 

11,301,727

 

8,543,080

 

5,155,193

Post-Reverse Stock Split and Authorized Shares Reduction 1:16

 

22,500,000

 

9,889,011

 

7,475,195

 

5,135,794

Post-Reverse Stock Split and Authorized Shares Reduction 1:18

 

20,000,000

 

8,790,232

 

6,644,617

 

4,565,151

Post-Reverse Stock Split and Authorized Shares Reduction 1:20

 

17,500,000

 

7,911,209

 

5,980,156

 

3,608,635

____________

(1)      Includes an estimate of approximately 5 million shares that may be issuable as a result of in-kind interest payments on the Series A Convertible Preferred Stock.

9

Table of Contents

As illustrated in the table above, and as detailed under “Relationship Between the Reverse Stock Split Ratio and the Authorized Shares Reduction,” the Authorized Shares Reduction will result in a reduction of the total number of shares of common stock and the total number of authorized shares of all classes of stock that we are authorized to issue, but that reduction may not always be proportional to the split ratio. Further, the Authorized Shares Reduction would not have any effect on the rights of existing stockholders, and the par value of our common stock would remain unchanged at $0.00001 per share. As of July 28, 2023, we did not have any shares of common stock that were issued, but not outstanding.

The number of authorized shares of our preferred stock and the number of shares of our Series A Convertible Preferred Stock that are issued and outstanding will not change as a result of the proposed Reverse Stock Split and Authorized Shares Reduction, but the applicable terms of our Series A Convertible Preferred Stock (including those governing conversion rights) will be adjusted for the Reverse Stock Split that is effected in accordance with the terms of our Series A Convertible Preferred Stock.

After the Effective Time, our common stock would have a new Committee on Uniform Securities Identification Procedures, or CUSIP number, a number used to identify our common stock.

Our common stock is currently registered under Section 12(b) of the Exchange Act, and we are subject to the periodic reporting and other requirements of the Exchange Act. The implementation of the Reverse Stock Split will not affect the registration of our common stock under the Exchange Act. Our common stock would continue to be listed on Nasdaq under the symbol “CPTN” immediately following the Reverse Stock Split, subject to our regaining compliance with Nasdaq’s minimum bid price requirement by October 10, 2023 and our ability to otherwise satisfy Nasdaq’s continued listing requirements.

Effect of Reverse Stock Split on Stated Capital

Pursuant to the Reverse Stock Split, the par value of our common stock will remain $0.00001 per share. As a result of the Reverse Stock Split, at the Effective Time, the stated capital on our balance sheet attributable to common stock (subject to a minor adjustment in respect of the treatment of fractional shares) and the additional paid-in capital account will, in total, not change due to the Reverse Stock Split. However, the allocation between the stated capital attributable to common stock and the additional paid-in capital on our balance sheet will change because there will be fewer shares of common stock issued and outstanding. The stated capital attributable to common stock will decrease, and in turn, the stated capital attributable to the additional paid-in capital will increase. The net income or loss per share of common stock will increase because there will be fewer shares of common stock issued and outstanding. The shares of common stock held in treasury, if any, will also be reduced based on the Reverse Stock Split ratio selected by the Board. The Reverse Stock Split would be reflected retroactively in our consolidated financial statements. We do not anticipate that any other accounting consequences would arise as a result of any Reverse Stock Split.

Shares Held in Book-Entry and Through a Broker, Bank or Other Holder of Record

The combination of, and reduction in, the number of issued shares of common stock as a result of the Reverse Stock Split will occur automatically at the Effective Time without any additional action on the part of our stockholders.

Upon the Reverse Stock Split, we intend to treat stockholders holding shares of common stock in “street name” (that is, through a broker, bank or other holder of record) in the same manner as registered stockholders whose shares of common stock are registered in their names. Brokers, banks or other holders of record will be instructed to effect the Reverse Stock Split for their beneficial holders holding shares of common stock in “street name”; however, these brokers, banks or other holders of record may apply their own specific procedures for processing the Reverse Stock Split. If you hold your shares of common stock with a broker, bank or other holder of record, and you have any questions in this regard, we encourage you to contact your broker, bank or holder of record.

If you hold registered shares of common stock in a book-entry form, you do not need to take any action to receive your post-Reverse Stock Split shares of common stock in registered book-entry form or your cash payment in lieu of fractional shares, if applicable. If you are entitled to post-Reverse Stock Split shares of common stock, a transaction statement will automatically be sent to your address of record as soon as practicable after the Effective Time indicating the number of shares of common stock you hold. In addition, if you are entitled to a payment of cash

10

Table of Contents

in lieu of fractional shares, a check will be mailed to you at your registered address as soon as practicable after the Effective Time. By signing and cashing this check, you will warrant that you owned the shares of common stock for which you received a cash payment. See “— Fractional Shares.”

Interest of Certain Persons in Matters to be Acted Upon

No officer or director has any substantial interest, direct or indirect, by security holdings or otherwise, in the Reverse Stock Split or the Authorized Shares Reduction that is different from, or in addition, to the interests of all of our other stockholders.

Reservation of Right to Delay the Filing of the Certificate of Amendment, or Abandon the Reverse Stock Split and the Authorized Shares Reduction

We reserve the right to delay the filing of the Certificate of Amendment or abandon the Reverse Stock Split and the Authorized Shares Reduction at any time before the Effective Time, even if the Reverse Stock Split has been approved by stockholders at the Special Meeting. By voting in favor of Proposal One, you are also expressly authorizing the Board to delay, until the one-year anniversary of the Special Meeting, or abandon all of the Split Amendments if the Board determines that such action is in the best interests of the Company and its stockholders. If the Board fails to implement the Reverse Stock Split prior to the one-year anniversary of this Special Meeting all of the Split Amendments will be deemed abandoned and stockholder approval would again be required prior to implementing any Reverse Stock Split.

Required Vote; Effect of Proposal

To be approved, this Proposal One requires the affirmative vote of a majority of the votes cast by the stockholders of the Company present in person or represented by proxy and entitled to vote thereon. Virtual attendance at our Special Meeting constitutes presence in person for the Special Meeting. If you hold your shares in “street name” (that is, your shares are held in an account at and registered in the name of a brokerage firm, bank, broker-dealer or similar organization), your broker or other organization may vote your shares under limited circumstances if you do not provide voting instructions before the Special Meeting. These circumstances include voting your shares on so-called “routine matters.” This Proposal One is a “routine” matter and, therefore, no broker non-votes are anticipated on this Proposal One. Abstentions will not be treated as votes “FOR” or “AGAINST” and will not be counted in determining the outcome of the vote on this Proposal One. Proxies solicited by the Board will be voted “FOR” approval of this Proposal One, unless otherwise specified. If stockholder approval for this Proposal One is not obtained, then the Reverse Stock Split and the Authorized Shares Reduction will not be effected.

No Appraisal Rights

Under the DGCL, our Second Amended and Restated Certificate of Incorporation and our Bylaws, stockholders have no rights to exercise dissenter’s or appraisal rights with respect to the Split Amendment to effect the Reverse Stock Split and the Authorized Shares Reduction.

Material U.S. Federal Income Tax Consequences of the Reverse Stock Split

The following discussion is a summary of material U.S. federal income tax consequences of the Reverse Stock Split to U.S. Holders (as defined below). This summary is based upon the Internal Revenue Code of 1986, as amended (the “Code”), the applicable U.S. Treasury Department regulations promulgated thereunder (the “Treasury Regulations”), published rulings and administrative pronouncements of the Internal Revenue Service (“IRS”), and judicial decisions, in each case in existence on the date hereof, all of which are subject to change. Any such change could apply retroactively and could adversely affect the tax consequences described below. No assurance can be given that the IRS will agree with the consequences described in this summary, or that a court will not sustain any challenge by the IRS in the event of litigation. No advance tax ruling has been or will be sought or obtained from the IRS regarding the tax consequences of the transactions described herein.

11

Table of Contents

For purposes of this summary, a “U.S. Holder” is a beneficial owner of shares of common stock that is (a) an individual who is a citizen of the United States or who is resident in the United States for U.S. federal income tax purposes, (b) an entity that is classified for U.S. federal income tax purposes as a corporation and that is organized under the laws of the United States, any state thereof, or the District of Columbia, or is otherwise treated for U.S. federal income tax purposes as a domestic corporation, (c) an estate the income of which is subject to U.S. federal income taxation regardless of its source, or (d) a trust (i) whose administration is subject to the primary supervision of a court within the United States and all substantial decisions of which are subject to the control of one or more United States persons as described in Section 7701(a)(30) of the Code (“United States persons”), or (ii) that has a valid election in effect under applicable Treasury Regulations to be treated as a United States person.

This summary does not discuss all U.S. federal income tax considerations that may be relevant to U.S. Holders in light of their particular circumstances, including consequences that may be relevant for U.S. Holders that may be subject to special treatment under U.S. federal income tax law (for example, tax-exempt organizations, S corporations, partnerships and other pass through entities (and investors therein), mutual funds, insurance companies, banks and other financial institutions, dealers in securities, brokers or traders in securities, commodities or currencies that elect to use a mark-to-market method of accounting, real estate investment trusts, regulated investment companies, individual retirement accounts, qualified pension plans, persons who hold shares of common stock as part of a straddle, hedging, constructive sale, conversion, or other integrated transaction, U.S. Holders that have a functional currency other than the U.S. dollar and persons who acquired shares of common stock as a result of the exercise of employee stock options or otherwise as compensation or through a tax-qualified retirement plan). Furthermore, this summary does not discuss any alternative minimum tax consequences or the Medicare contribution tax on net investment income, and does not address any aspects of U.S. state or local or non-U.S. taxation. This summary only applies to those beneficial owners that hold shares of common stock as “capital assets” within the meaning of Section 1221 of the Code (generally, property held for investment).

If an entity classified for U.S. federal income tax purposes as a partnership owns shares of common stock, the tax treatment of a member of the entity will depend on the status of the member and the activities of the entity and such member. The tax treatment of such an entity, and the tax treatment of any member of such an entity, are not addressed in this summary. Any entity that is classified for U.S. federal income tax purposes as a partnership and that owns shares of common stock, and any members of such an entity, are encouraged to consult their tax advisors.

U.S. HOLDERS OF SHARES OF COMMON STOCK ARE ENCOURAGED TO SEEK ADVICE FROM THEIR OWN TAX ADVISORS REGARDING THE U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT TAKING INTO ACCOUNT THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.

We intend to take the position that the Reverse Stock Split constitutes a recapitalization for U.S. federal income tax purposes pursuant to Section 368(a)(1)(E) of the Code. Assuming the Reverse Stock Split qualifies as a recapitalization:

•        a U.S. Holder will not recognize gain or loss on the Reverse Stock Split, except with respect to any cash received in lieu of a fractional share of common stock;

•        the aggregate tax basis of the shares of common stock received by a U.S. Holder in the Reverse Stock Split will be equal to the aggregate tax basis of the shares exchanged therefor (excluding any portion of such basis allocable to a fractional share); and

•        the holding period of the shares of common stock received by a U.S. Holder in the Reverse Stock Split will include the holding period of the shares exchanged therefor.

Treasury Regulations provide detailed rules for allocating the tax basis and holding period among shares of common stock which were acquired by a stockholder on different dates and at different prices. U.S. Holders that acquired shares of common stock on different dates or at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period among such shares.

12

Table of Contents

A stockholder who receives cash in lieu of a fractional share as a result of the Reverse Stock Split should generally be treated as having received the payment as a distribution in redemption of the fractional share, as provided in Section 302(a) of the Code. Generally, if redemption of the fractional shares of all stockholders meaningfully reduces the percentage of the total voting power held by a particular redeemed stockholder (determined by including the voting power held by certain related persons), the particular stockholder should recognize gain or loss equal to the difference, if any, between the amount of cash received and the stockholder’s basis in the fractional share. In the aggregate, such a stockholder’s basis in the reduced number of shares of common stock will equal the stockholder’s basis in its old shares of common stock decreased by the basis allocated to the fractional share for which such stockholder is entitled to receive cash, and the holding period of the reduced number of shares received will include the holding period of the old shares exchanged. If the redemption of the fractional shares of all stockholders leaves the particular redeemed stockholder with no meaningful reduction in the stockholder’s percentage of total voting power (determined by including the voting power held by certain related persons), it is likely that cash received in lieu of a fractional share would be treated as a distribution under Section 301 of the Code. The Internal Revenue Service has ruled that a small reduction by a minority shareholder whose relative stock interest is minimal and who exercises no control over the affairs of the corporation will satisfy this test. Stockholders should consult their own tax advisors regarding the tax consequences to them of a payment for fractional shares.

Payments of cash made in lieu of a fractional share of common stock may, under certain circumstances, be subject to information reporting and backup withholding. To avoid backup withholding, each U.S. Holder that does not otherwise establish an exemption should furnish on applicable IRS forms its taxpayer identification number and comply with the applicable certification procedures.

Backup withholding is not an additional tax and amounts withheld will be allowed as a credit against the holder’s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. U.S. Holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them.

PROPOSAL 1 — ELECTION OF DIRECTORS

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR ALLIN FAVOR OF THE
DIRECTOR NOMINEES. UNLESS OTHERWISE INSTRUCTED, THE PROXY HOLDERS
WILL VOTE THE PROXIES RECEIVED BY THEM “PROPOSAL ONE.
FOR ALL” THE DIRECTOR
NOMINEES.

Our Board of Directors (the “Board”) is currently comprised of seven directors. Under our amended and restated certificate of incorporation (the “Certificate of Incorporation”), our Board is divided into three classes, each serving a staggered three-year term and with one class being elected at each year’s annual meeting of stockholders as follows:

●      the Class A directors are Dr. Jun Ye, Dr. Mei (May) Wang and Mr. Hideharu (Harry) Konagaya, and their terms will expire at the Annual Meeting;

●      the Class B directors are Mr. George Syllantavos and Mr. Xiaogang (Jason) Zhang, and their terms will expire at the 2024 annual meeting of stockholders; and

●      the Class C directors are Dr. Jun Pei and Mr. Takayuki Katsuda, and their terms will expire at the 2025 annual meeting of stockholders.

Upon the recommendation of the Nominating and Corporate Governance Committee of our Board, our Board has nominated each of Dr. Jun Ye and Dr. Mei (May) Wang for election to our Board as Class A directors to serve until the 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified. Mr. Hideharu (Harry) Konagaya was nominated for election to our Board as a Class A director to serve until the 2026 annual meeting of stockholders by Koito Manufacturing Co., Ltd. (“Koito”), an affiliate of the Company, pursuant to the contractual rights granted to Koito pursuant to that certain Investor Rights Agreement, dated as of January 19, 2023, entered into by and between the Company and Koito. See “Transactions with Related Persons — Certain Relations and Related Party Transactions” below for more information.

Proxies may only be voted for the three Class A directors nominated for election at the Annual Meeting.

Each of Dr. Jun Ye, Dr. Mei (May) Wang and Mr. Hideharu (Harry) Konagaya are standing for election to our Board for the first time since we became a publicly traded company.

Each of the director nominees has consented to being named in this Proxy Statement and to serving as a director, if elected. We have no reason to believe that any of the nominees will be unable or unwilling for good cause to serve if elected. However, if any nominee should become unable for any reason or unwilling for good cause to serve, the proxy holders will vote the proxies received by them for another person nominated as a substitute by the Board (or, with respect to Mr. Hideharu (Harry) Konagaya, by Koito), or the Board may reduce the number of directors on the Board.

Biographical Descriptions

Set forth below is biographical information about each of our director nominees and continuing directors. The information below is provided as of April 6, 2023. The primary experience, qualifications, attributes, and skills of each of our director nominees that led to the conclusion of the Nominating and Corporate Governance Committee and the Board that such nominee should serve as a member of the Board are also described below.

CEPTON, INC.

2023 PROXY STATEMENT

3

13

Table of Contents

PROPOSAL 1TWO — ELECTION OF DIRECTORSVOTE ON ADJOURNMENT

Nominees for Election as Class A DirectorsIf at the AnnualSpecial Meeting

dR. jUN yE

Class A

Age: 56

Director Since: 2022

POSITION AND BUSINESS EXPERIENCE

Dr. Ye has served as a member of our Board since February 2022. Dr. Ye has also served as the President and CEO of Sentieon, Inc., a bioinformatics software development company, since co-founding it in July 2014. Dr. Ye previously served as the Co-founder, President and CEO of Founton Technologies, Inc., a company that specialized in datamining, which is now part of Alibaba Group, from May 2011 to June 2014. Prior to Founton, Dr. Ye was the Co-founder, President, and CTO of Brion Technologies, Inc., a company specializing in computational lithography for semiconductor manufacturing (acquired by ASML in December 2006), from September 2002 to April 2011. Dr. Ye was a consulting professor of electrical engineering at Stanford University from October 2001 to August 2015. Dr. Ye has a Ph.D. in electrical engineering from Stanford University, a M.S. in physics from Iowa State University and a B.S. in electrical engineering from Fudan University.

KEY ATTRIBUTES

Dr. Ye is qualified to serve on our Board based on his significant experience leading as an executive at technology-driven companies.

Dr. MEI (May) WANg

Class A

Age: 53

Director Since: 2022

POSITION AND BUSINESS EXPERIENCE

Dr. Wang has served as a member of our Board since February 2022. Dr. Wang has also served as the Chief Technology Officer, Internet of Things, of Palo Alto Networks, Inc. (Nasdaq:PANW) a multinational cybersecurity company, since September 2019, and as a Venture Partner at SAIF Partners, an Asian private equity firm, since November 2013. Previously, she served as the Chief Technology Officer and a board member of Zingbox Inc., an internet of things cybersecurity company (acquired by Palo Alto Networks in September 2019), until September 2019 after co-founding the company in November 2014. Prior to that, she served as the President and Chairman of the Board of the North America Chinese Clean-tech & Semiconductor Association from June 2007 to May 2010. Dr. Wang received her Ph.D. in Electrical Engineering from Stanford University.

KEY ATTRIBUTES

We believe that Dr. Wang is qualified to serve on our Board based on her extensive board, executive and investment experience at technology-driven companies.

Mr. Hideharu (Harry) Konagaya

Class A
Age: 59
Director Since: 
2023

POSITION AND BUSINESS EXPERIENCE

Mr. Konagaya has served as a member of our Board since January 2023. Since 2017, Mr. Konagaya also serves as the Senior Managing Director, Head of the Finance & Accounting Department, and Head of the Procurement Department of Koito Manufacturing Co., Ltd., which is a leading Japanese manufacturer of automotive lighting equipment, aircraft parts, electrical equipment, and other products, operating on a global basis, and listed on the Tokyo Stock Exchange. Mr. Konagaya has a degree in Industrial Management from the Faculty of Science and Engineering, Waseda University, in Japan.

KEY ATTRIBUTES

Mr. Konagaya is qualified to serve on our Board based on his significant experience in the automotive industry, with LiDAR technology and other automotive equipment.

4

2023 PROXY STATEMENT

CEPTON, INC.

PROPOSAL 1 — ELECTION OF DIRECTORS

Continuing Directors

Dr. Jun pei

Class C
Age: 54
Director Since: 2022

POSITION AND BUSINESS EXPERIENCE

Dr. Pei has served as our President, Chief Executive Officer and Chairman of the Board since February 2022. Prior to the merger of our legal predecessor, Growth Capital Acquisition Company (“GCAC”) into Cepton Technologies, Inc. (“Legacy Cepton”) in February 2022 (the “Business Combination”), Dr. Pei served as the CEO of Legacy Cepton since co-founding the company in 2016 until February 2022. Before that, Dr. Pei served as the CEO and founder of AEP Technology, Inc., an optical instrumentation company, from November 2010 to July 2017 and as a general manager of acoustic and lidar engineering at Velodyne Lidar, Inc., a lidar technology company, from May 2007 to November 2010. Dr. Pei received his Ph.D. in Electrical Engineering from Stanford University.

KEY ATTRIBUTES

We believe that Dr. Pei is qualified to serve on our Board based on his substantial business, leadership and management experience as our CEO and previous experience at instrumentation and lidar companies.

Mr. George Syllantavos

Class B
Age: 58
Director Since: 2019

POSITION AND BUSINESS EXPERIENCE

Mr. Syllantavos has served as a member of our Board since February 2022. Prior to the Business Combination, Mr. Syllantavos served as a member of the board of directors of GCAC since December 2019. As a director of GCAC, Mr. Syllantavos was designated to serve as the co-CEO and CFO of GCAC from December 2019 until the closing of the Business Combination in order to facilitate an acquisition. Previously, Mr. Syllantavos served as a board member and the Chair of the audit committee of ITHAX Acquisition Corp. N/K/A Mondee, Inc. (Nasdaq:MOND) from January 2021 to July 2022, as a board member of Phunware Inc. (Nasdaq:PHUN) from December 2018 to December 2021 and as co-CEO and CFO of Stellar Acquisition III Corp. N/K/A Phunware Inc. from December 2015 to December 2018. Mr. Syllantavos also co-founded Nautilus Energy Management Corp. and has served as a managing director since May 2011, and has served as partner of SevenSeas Investment Fund since 2018. Mr. Syllantavos holds a degree in industrial engineering from Roosevelt University and a M.B.A. from Northwestern University, Kellogg School of Management.

KEY ATTRIBUTES

We believe that Mr. Syllantavos is qualified to serve on our Board based on his significant business leadership and business operational experience serving as the CEO and CFO of several public companies.

CEPTON, INC.

2023 PROXY STATEMENT

5

PROPOSAL 1 — ELECTION OF DIRECTORS

Mr. Xiaogang (Jason) Zhang

Class B
Age: 57
Director Since: 2022

POSITION AND BUSINESS EXPERIENCE

Mr. Zhang has served as a member of our Board since February 2022. Mr. Zhang has also served as the managing partner of CFT Capital, a leading high tech industry investment fund management firm in China, since January 2018. During 2017, Mr. Zhang served as a consultant, advisor and/or board member to certain companies. Mr. Zhang previously served as the Managing Director, Asia Pacific of Delphi Automotive Inc. from August 2015 to December 2016, senior executive positions at Freescale Semiconductor Inc, NXP Semiconductors Co. Ltd., Philips China Investment Co. Ltd. In China. He was the CFO at T3G Technologies Inc. from 2004 to 2005, as assigned by Philips. Mr. Zhang has an M.B.A. from Insead, an M.S. in engineering from Stanford University and a B.S. in Engineering from Tsinghua University.

KEY ATTRIBUTES

We believe Mr. Zhang is qualified to serve on our Board based on his significant investment and business development experience in innovative technologies in the automotive, industrial, networking and consumer markets.

Mr. Takayuki Katsuda

Class C
Age: 60
Director Since: 2022

POSITION AND BUSINESS EXPERIENCE

Mr. Katsuda has served as a member of our Board since February 2022. Mr. Katsuda has served as the Managing Corporate Officer of Koito since June 2016 and as a member of the Legacy Cepton board since June 2019. Prior to Koito, Mr. Katsuda served as the Chief Engineer, Product Planning at Lexus International from January 2007 to March 2016. Mr. Katsuda holds a degree in Aeronautical Engineering from Kyushu University.

KEY ATTRIBUTES

We believe that Mr. Katsuda is qualified to serve on our Board based on his broad leadership experience in the automotive engineering industry.

6

2023 PROXY STATEMENT

CEPTON, INC.

CORPORATE GOVERNANCE

Corporate Governance Guidelines

Our Board has adopted Corporate Governance Guidelines there are not sufficient votes to assistapprove Proposal One (approval of the Split Amendments to effect the Reverse Stock Split and Authorized Shares Reduction), we intend to move to vote on this Adjournment Proposal. We do not intend to move for a vote on this Proposal Two if Proposal One is approved by the requisite number of shares of our common stock at the Special Meeting.

In this Adjournment Proposal, the Company’s stockholders are being asked to approve a proposal that will give the Board authority to adjourn the Special Meeting to a later date or time, if necessary, to solicit additional proxies in favor of Proposal One if there are insufficient votes at the dischargetime of its dutiesthe Special Meeting to approve Proposal One. If the stockholders approve this Adjournment Proposal, we could adjourn the Special Meeting and use the additional time to set forthsolicit additional proxies, including the Board’s current views with respect to selected corporate governance matters considered significant to our stockholders. Our Corporate Governance Guidelines direct our Board’s actions with respect to, amongsolicitation of proxies from stockholders that have previously voted. Among other things, our Board compositionapproval of this Adjournment Proposal could mean that, even if we had received proxies representing a sufficient number of votes “AGAINST” Proposal One to defeat such proposal, we could adjourn the Special Meeting without a vote on Proposal One and director qualifications, responsibilitiesseek to convince the holders of directors, director compensation, director orientation and continuing education, succession planning andthose shares to change their votes to votes in favor of Proposal One.

Required Vote

To be approved, this Proposal Two requires the Board’s annual performance evaluation. A current copy of our Corporate Governance Guidelines is available under “Corporate Governance” on our website at https://investors.cepton.com/.

Director Independence

Under the rules of The Nasdaq Stock Market LLC (“Nasdaq”) and our Corporate Governance Guidelines, independent directors must comprise a majority of our Board. Under the Nasdaq rules, a director will only qualify as an “independent director” if our Board affirmatively determines that the director, in the opinion of our Board, does not have a relationship which would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Our Board reviewed its composition and the independence of our directors and considered whether any director has a relationship with us that could interfere with his or her ability to exercise independent judgment in carrying out his or her responsibilities. In addition, the Nominating and Corporate Governance Committee of our Board annually evaluates and recommends to the Board a determination with respect to the independence of each our non-employee directors under the Nasdaq listing standards. As a part of the Nominating and Corporate Governance Committee’s evaluation process, and as part of the independence determinations by the Nominating and Corporate Governance Committee and the Board, the Nominating and Corporate Governance Committee and the Board, as applicable, each consider, in addition to such other factors as they may deem appropriate, each director’s occupation, personal and affiliate transactions with the Company, and other relevant direct and indirect relationships with the Company that may affect independence. Based upon information requested from and provided by each director concerning his or her background, employment, and affiliations, including family relationships, our Board has determined that each of Dr. Jun Ye, Mr. Xiaogang (Jason) Zhang, Mr. George Syllantavos and Dr. Mei (May) Wang qualify as independent directors, as defined under the listing rules of Nasdaq, and our Board consistsaffirmative vote of a majority of “independent directors,” as defined under the rulesvotes cast by the stockholders of the SECCompany present in person or represented by proxy and Nasdaq. In making these determinations,entitled to vote thereon. Virtual attendance at our Board consideredSpecial Meeting constitutes presence in person for the relationships that eachSpecial Meeting. If you hold your shares in “street name” (that is, your shares are held in an account at and registered in the name of a brokerage firm, bank, broker-dealer or similar organization), your broker or other organization may vote your shares under limited circumstances if you do not provide voting instructions before the Special Meeting. These circumstances include voting your shares on so-called “routine matters.” This Proposal Two is a “routine” matter, and, therefore, no broker non-employee-votes director has with usare anticipated on this Proposal Two. Abstentions will not be counted as votes “FOR” or “AGAINST” and all other facts and circumstances our Board deemed relevantwill not be counted in determining independence. Dr. Jun Pei is not an independent director as a resultthe outcome of his position as our President and Chief Executive Officer, and Mr. Takayuki Katsuda and Mr. Hideharu (Harry) Konagaya are not independent directors as a resultthe vote on this Proposal Two. Proxies solicited by the Board will be voted “FOR” approval of their affiliation with Koito.this Proposal Two, unless otherwise specified.

Board Leadership StructureTHE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF PROPOSAL TWO IF THERE ARE INSUFFICIENT VOTES AT THE SPECIAL MEETING TO APPROVE PROPOSAL ONE.

We have no policy requiring either that the positions of the Chairman of the Board and our Chief Executive Officer be separate or that they be occupied by the same individual. Our Board believes that it is important to retain flexibility to allocate the responsibilities of the offices of the Chairman of the Board and Chief Executive Officer in a way that is in our best interests and the best interests of our stockholders at a given point in time. Dr. Jun Pei currently serves as our Chief Executive Officer and Chairman of the Board. In connection with Dr. Jun Pei’s appointment as Chairman of our Board, the Board also created the position of Lead Independent Director and appointed Dr. Jun Ye to serve in that role.

CEPTON, INC.

2023 PROXY STATEMENT

7

14

Table of Contents

CORPORATE GOVERNANCE

As our Lead Independent Director, Dr. Jun Ye: (i) presides at executive sessions of independent directors; (ii) calls and develops agendas for meetings of our independent directors; (iii) serves as liaison between the independent directors and the Chairman of the Board and Chief Executive Officer; (iv) reviews meeting agendas and, where appropriate, other information provided to the Board, ensuring the quality, quantity, appropriateness and timeliness of such information; (v) facilitates the Board’s approval of the number and frequency of Board meetings; (vi) reviews meeting schedules to assure that there is sufficient time for discussion of all agenda items and (vii) ensures that he is available, when appropriate, for consultation and direct communication with stockholders.

The Board’s Role in Risk OversightHOLDINGS OF MAJOR STOCKHOLDERS, OFFICERS AND DIRECTORS

Our Board, as a whole and through its committees, serves an active role in overseeing the management of risks related to our business. Our officers are responsible for day-to-day risk management activities. The full Board monitors risks through regular reports from each of the committee chairs and is apprised of particular risk management issues in connection with its general oversight and approval of corporate matters. The Board and its committees oversee risks associated with their respective areas of responsibility, as summarized below. Each committee meets with key management personnel and representatives of outside advisers as required.

Our Board has delegated oversight for specific areas of risk exposure to its committees as follows:

●      The Audit Committee oversees the management of a variety of the Company’s risks, including through review and discussion of the Company’s guidelines and policies governing the process by which senior management of the Company and the relevant departments of the Company assess and manage the Company’s exposure to risk, and reviews of any significant financial risk exposures facing the Company and management’s plans to monitor, control, or minimize such exposures. The Audit Committee is also responsible for primary risk oversight related to our financial reporting, accounting, and internal controls, oversees risks related to our compliance with legal and regulatory requirements, and meets regularly with our internal auditors and independent registered public accounting firm.

●      The Compensation Committee oversees, among other things, the assessment and management of risks related to our compensation plans, policies and practices.

●      The Nominating and Corporate Governance Committee oversees, among other things, the impact of our Board’s leadership structure on the Board’s role in risk oversight.

The Compensation Committee identifies and considers risks related to our executive compensation, including during its review and approval of our executive compensation program. Our compensation programs are designed to reward our named executive officers and other employees for the achievement of the Company’s corporate strategies, business objectives and the creation of long-term value for stockholders, while at the same time avoiding the encouragement of unnecessary or excessive risk-taking. Annual incentive bonuses are balanced with long-term equity incentives that are subject to vesting schedules.

Our Board believes that the leadership structure described above under “Board Leadership Structure” facilitates the Board’s oversight of risk management because it allows the Board, with leadership from the Lead Independent Director and working through its independent committees, to participate actively in the oversight of management’s actions.

8

2023 PROXY STATEMENT

CEPTON, INC.

CORPORATE GOVERNANCE

Committees of the Board

The Board has three standing committees: the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. The written charters of these committees are available under “Corporate Governance” on our website at https://investors.cepton.com/.

Audit
Committee

Compensation
Committee

Nominating and
Corporate Governance
Committee

Dr. Jun Pei

Takayuki Katsuda

Hideharu (Harry) Konagaya

George Syllantavos

Dr. Mei (May) Wang

Dr. Jun Ye

Xiaogang (Jason) Zhang

 = Chairman of the Board   = Independent Director   = Member   = Financial Expert

CEPTON, INC.

2023 PROXY STATEMENT

9

CORPORATE GOVERNANCE

Audit Committee

Our Board determined that each of Mr. George Syllantavos, Dr. Mei (May) Wang and Mr. Xiaogang (Jason) Zhang, who comprise our Audit Committee, satisfy the independence standards for such committee established by applicable SEC rules and the listing standards of the Nasdaq. Additionally, our Board has determined that each of Mr. George Syllantavos and Mr. Xiaogang (Jason) Zhang is an “audit committee financial expert” as defined by applicable SEC rules.

Committee Members

Primary Responsibilities

Number of
Meetings in
2022

George Syllantavos (Chair) Dr. Mei (May) Wang Xiaogang (Jason) Zhang

•   Appointing, compensating, retaining and overseeing the work of our independent auditors.

•   Evaluating the performance, independence and qualifications of our independent auditors.

•   Monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to financial statements or accounting matters.

•   Reviewing the integrity, adequacy and effectiveness of our internal control policies and procedures.

•   Preparing the audit committee report required by the SEC to be included in our annual proxy statement.

•   Discussing the scope and results of the audit with our independent auditors, and reviewing with management and our independent auditors our interim and year-end operating results.

•   Establishing and overseeing procedures for employees to submit concerns anonymously about questionable accounting or auditing matters.

•   Reviewing our guidelines and policies on risk assessment and risk management.

•   Reviewing and approving related party transactions.

•   Obtaining and reviewing a report by our independent auditors at least annually, that describes our independent auditors internal quality control procedures, any material issues raised by review under such procedures, and any steps taken to deal with such issues when required by applicable law.

•   Approving (or, as permitted, pre-approving) all audit and non-audit services to be performed by our independent auditors.

5

The Audit Committee may form subcommittees and delegate to its subcommittees such power and authority as it deems appropriate from time to time under the circumstances. The Audit Committee has no current intention to delegate any of its responsibilities to a subcommittee.

10

2023 PROXY STATEMENT

CEPTON, INC.

CORPORATE GOVERNANCE

Compensation Committee

Our Board determined that each of Dr. Jun Ye, Mr. George Syllantavos and Dr. Mei (May) Wang, who comprise our Compensation Committee, satisfy the independence standards for such committee established by applicable SEC rules and the listing standards of the Nasdaq. In making its independence determination for each member of the Compensation Committee, our Board considered whether the director has a relationship with the Company that is material to the director’s ability to be independent from management in connection with the duties of a Compensation Committee member.

Committee Members

Primary Responsibilities

Number of
Meetings in
2022

Dr. Jun Ye (Chair) George Syllantavos Dr. Mei (May) Wang

•   Retaining compensation consultants and outside service providers and advisors.

•   Reviewing and approving, or recommending that our Board approve, the compensation of our executive officers, including annual base salary, long- and short-term incentive plans, retirement plans, deferred compensation plans, equity award plans and other benefits.

•   Reviewing and recommending to our Board the compensation of our non-employee directors.

•   Administering and determining any award grants under our equity and non-equity incentive plans.

•   Reviewing and evaluating succession plans for our executive officers.

•   Preparing the compensation committee report required by the SEC to be included in our annual proxy statement.

•   Periodically reviewing our practices and policies of employee compensation as they relate to risk management and risk-taking incentives.

2

The Compensation Committee may form subcommittees and delegate to its subcommittees such power and authority as it deems appropriate from time to time under the circumstances. The Compensation Committee has delegated certain limited authority to grant equity incentive awards under the 2022 Equity Incentive Plan to the Stock Award Committee, which consists of our Chairman and Chief Executive Officer, Dr. Jun Pei. The Compensation Committee has not otherwise delegated any of its responsibilities to subcommittees. The Compensation Committee may confer with the Board in determining the compensation for the Chief Executive Officer. In determining compensation for executive officers other than the Chief Executive Officer, the Compensation Committee considers, among other things, the recommendations of the Chief Executive Officer.

Pursuant to its charter, the Compensation Committee is authorized to retain or obtain the advice of compensation consultants, legal counsel or other advisors to assist in the evaluation of director and executive officer compensation or in carrying out its other responsibilities.

CEPTON, INC.

2023 PROXY STATEMENT

11

CORPORATE GOVERNANCE

Nominating and Corporate Governance Committee

Our Board determined that each of Dr. Jun Ye, Mr. George Syllantavos, and Mr. Xiaogang (Jason) Zhang, who comprise our Nominating and Corporate Governance Committee, satisfy the independence standards for such committee established by applicable SEC rules and the listing standards of the Nasdaq. In making its independence determination for each member of the Compensation Committee, our Board considered whether the director has a relationship with the Company that is material to the director’s ability to be independent from management in connection with the duties of a Nominating and Corporate Governance Committee member.

Committee Members

Primary Responsibilities

Number of
Meetings in
2022

Dr. Jun Ye (Chair) George Syllantavos Xiaogang (Jason) Zhang

•   Identifying, evaluating and recommending individuals qualified to become members of our Board and its committees.

•   Evaluating the performance of our Board and of individual directors.

•   Reviewing the Company’s environmental and social responsibility policies and practices.

•   Developing and recommending corporate governance guidelines to our Board.

•   Overseeing an annual evaluation of our Board and management.

0

The Nominating and Corporate Governance Committee may form subcommittees and delegate to its subcommittees such power and authority as it deems appropriate from time to time under the circumstances. The Nominating and Corporate Governance Committee has no current intention to delegate any of its responsibilities to a subcommittee. In 2022, the Nominating and Corporate Governance Committee did not retain a third-party search firm to assist in the process of identifying and evaluating potential director candidates.

Meetings and Attendance

During fiscal 2022, our Board held 6 meetings, the Audit Committee held 5 meetings, the Compensation Committee held 2 meetings, and the Nominating and Corporate Governance Committee held 0 meetings. Each of our directors attended at least 75% of the aggregate meetings of the Board and the committees of the Board on which he or she served during fiscal 2022. In addition, independent directors of our Board meet in regularly scheduled sessions without management.

It is our policy that directors are invited and encouraged to attend each year’s annual meeting of stockholders, either in person, telephonically or virtually.

Succession Planning

Our Board recognizes that advance planning for contingencies such as the departure, death or disability of the Chief Executive Officer or other top executives is critical so that, in the event of an untimely vacancy, the Company has in place a succession plan to facilitate the transition to both interim and longer-term leadership. The Compensation Committee is developing the Company’s executive succession plan, including our emergency succession plan, with input from appropriate members of management.

12

2023 PROXY STATEMENT

CEPTON, INC.

CORPORATE GOVERNANCE

Consideration of Director Candidates

Our Board and the Nominating and Corporate Governance Committee will consider director candidates recommended for election to the Board by stockholders in the same manner and using the same criteria as that used for any other director candidate. The Nominating and Corporate Governance Committee has not established any specific minimum qualifications that must be met by a director candidate. In evaluating a director candidate, the Nominating and Corporate Governance Committee will consider whether the composition of the Board reflects the appropriate balance of independence, sound judgment, business specialization, understanding of our business environment, willingness to devote adequate time to Board duties, technical skills, diversity and other background, experience and qualities as determined by the Nominating and Corporate Governance Committee. Stockholders who wish to recommend a director candidate for consideration by the Nominating and Corporate Governance Committee and the Board should submit their recommendation in writing to the chairperson of the Nominating and Corporate Governance Committee, care of the Corporate Secretary of the Company, no later than December 8, 2023. Such recommendation must include all information about the stockholder and the candidate otherwise required for director nominations by a stockholder pursuant to our Bylaws. The Nominating and Corporate Governance Committee may request additional information concerning such director candidate as it deems reasonably required to determine the eligibility and qualification of the director candidate to serve as a member of the Board. As discussed under “Transactions with Related Persons — Certain Relations and Related Party Transactions” below, Koito has certain rights regarding director nominees under the Investor Rights Agreement (as defined below).

While our Board has no formal policy for the consideration of diversity in identifying director nominees, the Nominating and Corporate Governance Committee seeks to have a board of directors that will reflect a balance of experience, qualifications, diversity, attributes and skills desirable for the Board as a whole.

Age

Tenure

Average Board Age: 57 years

Average Board Tenure: 1 year

4/7
Independent

86%
Women and Minority

86%
Other Public Company
Experience

Board Diversity Matrix (as of April6, 2023)

Total Number of Directors

7

 

Female

Male

Part I: Gender Identity

Directors

1

6

Part II: Demographic Background

African American or Black

0

0

Alaskan Native or American Indian

0

0

Asian

1

5

Hispanic or Latinx

0

0

Native Hawaiian or Pacific Islander

0

0

White

0

1

Two or More Races or Ethnicities

0

0

LGBTQ+

0

0

Did Not Disclose Demographic Background

0

0

No director self-reported as non-binary or did not disclose gender identity.

CEPTON, INC.

2023 PROXY STATEMENT

13

CORPORATE GOVERNANCE

Stockholders who wish to nominate a person for election as a director in connection with an annual meeting of stockholders (as opposed to making a recommendation to the Nominating and Corporate Governance Committee as described above) must deliver written notice to our Corporate Secretary in the manner described in our Bylaws, and as described further under “Proposals of Stockholders and Director Nominations for 2023 Annual Meeting” below.

Communications with the Board

The Board has established a process to receive communications from stockholders and other interested parties. Stockholders and other interested parties may communicate directly with members of the Board, the independent directors, or the Chairman of the Board by submitting a communication in an envelope marked “Confidential” addressed to the “Board of Directors,” “Independent Members of the Board of Directors,” or “Chairman,” as applicable, at: 399 West Trimble Road, San Jose, California 95131.

Policy on Pledging and Hedging of Company Shares

As part of our Insider Trading Policy adopted by our Board and applicable to our directors, officers and employees, certain contractors, consultants or other persons designated as insiders, their immediate family members and other persons sharing the same household, any corporations, partnership or other entities that such person controls or manages and any trust for which such person is the trustee or has a beneficial pecuniary interest (collectively, “Insiders”), Insiders are not permitted to trade in Company securities while in possession of material nonpublic information about the Company, engage in short sales of Company securities, engage in transactions in put options, call options or other derivative securities, on an exchange or in any other organized market in connection with Company securities, pledge Company securities as collateral for a loan or margin Company securities in a margin account or purchase financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engage in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Company securities.

Code of Ethics and Code of Business Conduct and Ethics

We have adopted a written code of conduct and ethics that applies to each of our employees, officers and directors. A current copy of the code is posted under “Corporate Governance” on our website at https://investors.cepton.com/. To the extent required by rules adopted by the SEC and Nasdaq, we intend to promptly disclose future amendments to certain provisions of the code, or waivers of such provisions granted to executive officers and directors, on our website at https://investors.cepton.com/.

14

2023 PROXY STATEMENT

CEPTON, INC.

DIRECTOR COMPENSATION

Non-Employee Director Compensation

Under our Director Compensation Policy, which was adopted on June 30, 2022, annual compensation for the members of our Board who are not employed by us or any of our subsidiaries (referred to in this section as “non-employee directors”) consists of an annual cash retainer, an additional cash retainer for non-employee directors serving in certain positions as described below, and equity awards as described below. Members of the Board are also reimbursed for their reasonable out-of-pocket expenses, including travel and lodging, incurred in attending meetings of the Board and Board committees or in connection with Board-related business, in each case consistent with our expense reimbursement policy. Our Board reserves the right to modify the Director Compensation Policy from time to time.

Annual Cash Retainers

Our Director Compensation Policy provides annual cash retainers for our non-employee directors as follows:

Annual Retainer

$40,000

Additional Committee Chair Retainers:

Audit Committee Chair

$15,000

Compensation Committee Chair

$10,000

Nominating and Corporate Governance Committee Chair

$8,000

Additional Committee Retainers:

Audit Committee

$10,000

Compensation Committee

$8,000

Nominating and Corporate Governance Committee

$5,000

These retainers are paid on a quarterly basis, in arrears, and are pro-rated if the director serves for a portion of a quarter in the applicable position.

Equity Compensation

Our Director Compensation Policy provides that on the date of our annual meeting of stockholders (or, for 2022, a date determined by our Board), each non-employee director continuing in office after that date will be granted an award of restricted stock units (“RSUs”) under our equity incentive plan, with the number of RSUs covered by the award to be determined by dividing $120,000 by the closing price of our stock on the grant date (or the preceding trading day if the grant date is not a trading day), rounded to the nearest whole share. The award will be scheduled to vest on the day immediately preceding our next annual meeting of shareholders (or, if earlier, the first anniversary of the grant date), subject to the non-employee director’s continued service on the Board.

In addition, if a new non-employee director is appointed or elected to the Board (other than at an annual meeting in connection with which the non-employee director receives an annual equity award as described above), the non-employee director will receive a pro-rated RSU award under our equity incentive plan upon joining the Board, with the number of RSUs covered by the award to be determined by dividing (i) the product of $120,000 multiplied by a fraction (not greater than one and not less than zero), the numerator of which is 365 minus the number of calendar days that had elapsed as of the date the director’s appointment or election to the Board since the date of the last annual meeting and the denominator of which is 365 by (ii) the closing price of our stock on the grant date (or the preceding trading day if the grant date is not a trading day), rounded to the nearest whole share. This initial RSU award will be scheduled to vest on the same vesting date as the equity awards granted to non-employee directors in connection with our last annual meeting of shareholders.

CEPTON, INC.

2023 PROXY STATEMENT

15

DIRECTOR COMPENSATION

RSU awards granted to our non-employee directors that are then outstanding will generally vest in full upon a change in control of the Company. The Board may approve other grants of equity-based awards to non-employee directors from time to time on such terms as it determines appropriate.

Pursuant to the Director Compensation Policy, we granted each of Dr. Mei (May) Wang, Mr. Xiaogang (Jason) Zhang and Mr. George Syllantavos an award of 76,923 RSUs on June 30, 2022, with each such award to vest on the date of our 2023 annual meeting of stockholders (or, if earlier, June 30, 2023).

Director Compensation Table — Fiscal 2022

The following table sets forth the total compensation paid to our non-employee directors for their service on our Board during fiscal 2022. Dr. Jun Pei, who is employed by us, does not receive any compensation for his service on the Board.

 

Name

 

Fees
Earned or
Paid in
Cash ($)

 

Stock
Awards ($)
(1)(2)

 

Option
Awards ($)
(1)(2)

 

All Other
Compensation ($)

 

Total ($)

  

Dr. Winston Fu(3)

 

60,000

 

223,500

 

 

 

283,500

 

Takayuki Katsuda(4)

 

 

 

 

 

 

George Syllantavos

 

51,000

 

120,000

 

 

 

171,000

 

Dr. Mei (May) Wang

 

43,500

 

120,000

 

 

 

163,500

 

Dr. Jun Ye(5)

 

 

 

 

 

 

Xiaogang (Jason) Zhang

 

36,667

 

120,000

 

 

 

156,667

 

(1)      Represents the aggregate grant date fair value of the stock awards and option awards granted to the non-employee director in 2022. These values have been determined under the principles used to calculate the value of equity awards for purposes of our financial statements. For a discussion of the assumptions and methodologies used to calculate the amounts referred to above, please see the discussion of equity incentive awards contained in Note 12, Stock-Based Compensation, to our financial statements included in our annual report on Form 10-K for 2022, filed with the SEC on March 20, 2023. The amounts reported in these columns reflect the accounting cost for these awards and do not correspond to the actual economic value that may be received by the non-employee director pursuant to the awards.

(2)      The aggregate number of outstanding and unvested RSUs and outstanding and unexercised stock options held by each non-employee director as of December 31, 2022 are set forth below. No non-employee director held any other outstanding equity awards as of that date.

Director

Number of
Outstanding Stock
Awards as of
12
/31/22

Number of
Outstanding Stock
Options as of
12
/31/22

Dr. Winston Fu

Takayuki Katsuda

George Syllantavos

76,923

Dr. Mei (May) Wang

76,923

Dr. Jun Ye

Xiaogang (Jason) Zhang

76,923

(3)      Dr. Winston Fu was employed by us and served as a member of our Board until November 2022. The compensation reported in the table above represents his compensation as an employee. He did not receive any compensation for his service on the Board during 2022.

(4)      Mr. Takayuki Katsuda declined the compensation he would have otherwise been entitled to receive under our Director Compensation Policy for his service on the Board during 2022.

(5)      Dr. Jun Ye declined the compensation he would have otherwise been entitled to receive under our Director Compensation Policy for his service on the Board during 2022.

16

2023 PROXY STATEMENT

CEPTON, INC.

EXECUTIVE OFFICERS OF THE COMPANY

The table below sets forth certain information regarding our executive officers as of April 6, 2023:

Name

Age

Position

Dr. Jun Pei

54

President, Chief Executive Officer & Chairman of the Board

Hull Xu

49

Chief Financial Officer

Dr. Liqun Han

53

Chief Operating Officer

Dr. Dongyi Liao

47

Chief Technology Officer

See “Proposal One — Election of Directors” for information concerning the business experience of Dr. Jun Pei. Information concerning the business experience of our other executive officers is set forth below.

Hull Xu

Mr. Xu has served as our Chief Financial Officer since April 2022. Mr. Xu previously served as the Company’s Vice President of Finance and Strategy from February 2022 until April 2022, and served in such role for Legacy Cepton since January 2021. Prior to joining Legacy Cepton, from November 2015 to January 2021, Mr. Xu was a Director and head of Electronics and Automotive Technology coverage at RBC Capital Markets. From September 2014 to November 2015, Mr. Xu was a Vice President at Barclays Investment Bank, covering the global Electronics industry. Additionally, from June 2013 to September 2014, Mr. Xu was an Executive Director, Head of Technology Origination at GE Capital. He also previously spent six years with Barclays Investment Bank covering the Technology industry from July 2008 to June 2013. Mr. Xu began his career as an electrical engineer at HP Inc. (NYSE:HPQ) and later at Agilent Technologies, Inc. (NYSE:A) and Turin Networks, Inc. Mr. Xu has an M.B.A. from the Haas School of Business at the University of California, Berkeley, an M.S. in Electrical Engineering from Stanford University and a B.S. in Electrical Engineering from the University of California, Davis.

Dr. Liqun
Han

Dr. Han has served as our Chief Operating Officer since August 2022. Dr. Han previously served as the Senior Vice President of Operations of Cepton from February 2022 to July 2022, Senior Vice President of Operations of Legacy Cepton from September 2020 to February 2022 and as the Vice President of Operations of Legacy Cepton from October 2016 to September 2020. Previously, Dr. Han was Director of Engineering & Technology at KLA-Tencor, responsible for core technology innovation and new product introduction. Dr. Han received a Ph.D. in Applied Physics and a M.S. in Electrical Engineering from Stanford University, with a specialty in solid-state electronics and optics.

Dr. Dongyi
Liao

Dr. Liao was promoted to Chief Technology Officer in March 2023 and previously served as our Senior Vice President of Applications since February 2022. Dr. Liao was the Vice President of Applications of Legacy Cepton from February 2017 to June 2019 and has previously served as the Senior Vice President of Applications of Legacy Cepton since June 2019 until the closing of the Business Combination. Dr. Liao previously co-founded YourMechanic.com and served as its Chief Technology Officer from January 2012 until December 2016. He also served in various engineering and managerial roles at NVIDIA from 2001 to 2010. Dr. Liao has a Ph.D. in Nuclear Engineering from Massachusetts Institute of Technology.

There are no family relationships between or among any of our executive officers or directors.

CEPTON, INC.

2023 PROXY STATEMENT

17

EXECUTIVE COMPENSATION

Our compensation program is designed to align executives’ compensation with our business objectives and the creation of stockholder value, while helping us to continue to attract, motivate and retain individuals who contribute to the long-term success of the company. Compensation for our executive officers has three primary components: base salary, an annual cash incentive bonus opportunity, and long-term equity-based incentive compensation granted under our 2022 Equity Incentive Plan (the “2022 Plan”).

Our Compensation Committee reviews our executive officers’ overall compensation packages on an annual basis (or more frequently as it deems warranted) to help ensure we continue to attract and retain highly talented executives and provide appropriate incentives to create additional value for our stockholders.

As an emerging growth company and a smaller reporting company, we have opted to comply with the executive compensation disclosure rules applicable to “smaller reporting companies” (as such term is defined under applicable securities laws), which require compensation disclosure for our principal executive officer and the two most highly compensated executive officers other than our principal executive officer. In certain circumstances, the compensation of former executive officers may also need to be disclosed. The table below sets forth the annual compensation for services rendered during 2022 by these executive officers, also referred to as our named executive officers (“NEOs”).

Summary Compensation Table — Fiscal Years 2021-2022

Name and Principal
Position

 

Year

 

Salary
($)

 

Bonus
($)

 

Stock
Awards
($)
(1)

 

Option
Awards
($)
(1)

 

Non-Equity
Incentive Plan
Compensation
($)

 

Non-Qualified
Deferred
Compensation
Earnings ($)

 

All Other
Compensation
($)

 

Total
($)

Dr. Jun Pei

 

2022

 

312,385

 

 

596,000

 

 

 

 

 

908,385

Chief Executive
Officer

 

2021

 

265,108

 

 

 

 

 

 

 

265,108

Mr. Hull Xu(2)

 

2022

 

268,000

 

 

1,723,520

 

 

 

 

 

1,991,520

Chief Financial
Officer

                  

Dr. Liqun Han

 

2022

 

272,385

 

 

890,000

 

 

 

 

 

1,162,385

Chief Operating
Officer

 

2021

 

224,339

 

 

 

 

 

 

 

224,339

(1)      Represents the aggregate grant date fair value of the stock awards and option awards granted to the named executive officer in 2022. These values have been determined under the principles used to calculate the value of equity awards for purposes of our financial statements. For a discussion of the assumptions and methodologies used to calculate the amounts referred to above, please see the discussion of equity incentive awards contained in Note 12, Stock-Based Compensation, to our financial statements included in our annual report on Form 10-K for 2022, filed with the SEC on March 20, 2023. The amounts reported in these columns reflect the accounting cost for these awards and do not correspond to the actual economic value that may be received by the named executive officer pursuant to the awards.

The amount reported in this column for Mr. Hull Xu includes a grant date fair value of $54,720 for an award of performance-based restricted stock units as described in note (5) of the Outstanding Equity Awards table below. This value has been determined based on the probable outcome (determined as of the grant date) of the performance-based conditions applicable to the award. The grant date fair value of this award assuming that the highest level of performance conditions will be achieved is $166,880.

(2)      Mr. Hull Xu was appointed our Chief Financial Officer, effective April 5, 2022. He did not serve in an executive officer position during 2021.

18

2023 PROXY STATEMENT

CEPTON, INC.

EXECUTIVE COMPENSATION

Outstanding Equity Awards as of December 31, 2022

The following table provides information regarding outstanding stock options and restricted stock units held by each of our NEOs as of December 31, 2022, including the vesting dates for the portions of these awards that had not vested (and the fair market value of unvested restricted stock units) as of that date. Our NEOs did not hold any other outstanding equity awards as of that date.

 

Option Awards

 

Stock Awards

Name

 

Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable

 

Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable

 

Option
Exercise
Price
($)

 

Option
Expiration
Date

 

Number of
Shares
 or
Units of
Stock That Have
Not
Vested
(#)

 

Market
Value of
Shares or
Units of
Stock That Have
Not
Vested
($)
(1)

 

Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights
That Have
Not
Vested
(#)

 

Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights That Have Not
Vested
($)
(1)

Dr. Jun Pei

 

 

 

 

 

 

200,000

(2)

 

254,000

 

 

 

Mr. Hull Xu

 

293,401

 

318,907

(3)

 

1.26

 

2/11/2031

 

 

 

 

 

 

  

 

 

 

 

 

560,000

(4)

 

711,200

 

 

 

  

 

 

 

 

 

 

 

 

56,000

(5)

 

71,120

Dr. Liqun Han

 

1,959,387

 

 

 

0.10

 

11/15/2026

 

 

 

 

 

 

  

377,591

 

112,255

(6)

 

0.97

 

11/20/2029

 

 

 

 

 

 

  

 

 

 

 

 

200,000

(2)

 

254,000

 

 

 

  

 

 

 

 

 

200,000

(7)

 

254,000

 

 

 

(1)      The amounts in these columns have been determined by multiplying the number of shares or units, as applicable, by the closing price of a share of our common stock on December 30, 2022 (i.e., the last trading day of fiscal 2022).

(2)      The RSUs subject to these awards vest in two equal installments on May 20, 2023 and May 20, 2024.

(3)      The unvested portion of this option vests in 25monthly installments from January 19, 2023 through January 19, 2025.

(4)      The RSUs subject to this award vest in the following installments: 220,000 of the RSUs on May 20, 2023, 220,000 of the RSUs on May 20, 2024 and 120,000 RSUs will vest on May 20, 2025.

(5)      Represents performance-based stock units (“PSUs”), each of which represents a contingent right to receive one share of the Company’s common stock. The award will vest as to 30,000 of the PSUs if, at the close of regular trading for 20 trading days out of any period of 30 consecutive trading days, either (i) the Company’s closing stock price (in regular trading) exceeds $15.00 per share or (ii) the Company’s market capitalization exceeds $2.1 billion; and will vest as to the remaining 26,000 PSUs if, at the close of regular trading for 20 trading days out of any period of 30 consecutive trading days, either (i) the Company’s closing stock price (in regular trading) exceeds $17.50 per share or (ii) the Company’s market capitalization exceeds $2.5 billion, provided in each case that the applicable stock price or market capitalization goal must be achieved no later than February 10, 2025 for the applicable tranche to vest, and provided further that the vesting of each tranche is subject to continued employment with the Company through the day on which the applicable goal is achieved.

(6)      The unvested portion of this option vests in 11monthly installments from January 20, 2023 through November 20, 2023.

(7)      The RSUs subject to this award vest in four equal installments on August 20, 2023, August 20, 2024, August 20, 2025 and August 20, 2026.

CEPTON, INC.

2023 PROXY STATEMENT

19

EXECUTIVE COMPENSATION

2022 Equity Grants

On May 3, 2022, Dr. Jun Pei and Dr. Liqun Han were each granted an award of 200,000 RSUs that will vest in two equal installments on May 20, 2023 and May 20, 2024, and Mr. Hull Xu was granted (i) an award of 560,000 RSUs (that will vest as to 220,000 RSUs on May 20, 2023 and May 20, 2024 and as to 120,000 RSUs on May 20, 2025), and (ii) an award of 56,000 PSUs (that will vest based on achievement of stock price or market capitalization goals as described in note (5) to the Outstanding Equity Awards table above). Dr. Liqun Han was granted an additional award of 200,000 RSUs on July 29, 2022 that will vest in four equal installments on August 20, 2023, August 20, 2024, August 20, 2025 and August 20, 2026. Each of these awards was granted under, and is subject to the terms of, the 2022 Plan.

The 2022 Plan is administered by the Compensation Committee, which has authority to interpret the plan provisions and make all required determinations under the plan. This authority includes, subject to the provisions of the 2022 Plan, selecting participants and determining the type(s) of award(s) that they are to receive, determining the number of shares that are to be subject to awards and the terms and conditions of awards, including the price (if any) to be paid for the shares or the award, accelerating or extending the vesting or exercisability or extending the term of any or all outstanding awards, making certain adjustments to an outstanding award and authorizing the conversion, succession or substitution of an award, determining the manner in which the purchase price of an award or the Company’s common stock may be paid, making required proportionate adjustments to outstanding awards upon the occurrence of certain corporate events such as reorganizations, mergers and stock splits, and making provisions to ensure that any tax withholding obligations incurred in respect of awards are satisfied. Awards granted under the plan are generally only transferable to a beneficiary of the participant upon his or her death or, in certain cases, to family members for tax or estate planning purposes.

Under the terms of the 2022 Plan, a change in control of the Company does not automatically trigger vesting of the awards then outstanding under the plan. If there is a change in control, each participant’s outstanding awards granted under the plan will generally be assumed by the successor company, unless the compensation committee provides that the award will not be assumed and will become fully vested and, in the case of options, exercisable, any options that become vested in connection with a change in control will generally terminate to the extent they are not exercised prior to the change in control.

Non-Equity Incentive Plan Compensation

While each of the NEOs was eligible to receive a discretionary cash bonus for 2022, the Compensation Committee determined not to award bonuses to any of the NEOs in order to help the Company conserve cash. In February 2023, the Compensation Committee approved a grant of RSUs to each of the NEOs under the 2022 Plan (196,923 RSUs for Dr. Jun Pei and 172,308 RSUs for each of Mr. Hull Xu and Dr. Liqun Han) that will vest in three equal annual installments on February 20, 2024, February 20, 2025 and February 20, 2026. Under SEC rules, equity awards are reported in the Summary Compensation Table as compensation for the fiscal year in which the award is granted. Accordingly, these award grants will be reported in the Summary Compensation Table as compensation for 2023 in the proxy statement for the Company’s 2024 annual meeting.

Executive Employment and Severance Agreements

We have entered into employment agreements with each of the NEOs. The employment agreements do not have a specified term and provide that the executive’s employment with the Company is at-will. Each employment agreement provides for the executive to receive a base salary and to participate in the Company’s benefit plans made available to employees generally. The letters do not provide for any severance or other benefit upon a termination of the executive’s employment.

20

2023 PROXY STATEMENT

CEPTON, INC.

EXECUTIVE COMPENSATION

Dr. Jun Pei’s employment agreement provides for an initial annual base salary of $320,000 and is eligible for an annual discretionary bonus as determined by the Compensation Committee and to participate in the Company’s benefit plans made available to employees generally. If Dr. Jun Pei’s employment with the Company is terminated by the Company without “cause” or by him for “good reason” (as defined in the agreement), he will receive severance of 18 months base salary (or $900,000 if such termination occurs prior to February 10, 2024), payable in installments over an 18-month period, payment of his COBRA premiums for 18 months, and 18 months’ accelerated vesting of his then-outstanding and unvested equity awards granted by the Company. However, if such a termination of his employment occurs in connection with or within 18 months following a change in control of the Company, his severance will equal the sum of 18 months of his base salary and one and one-half times his annual target bonus for the year of termination (or, if no target bonus has been established, the amount of his actual bonus for the prior year and provided that his severance will not be less than $900,000 if such termination occurs within two years after the closing) and will be paid in a lump sum; and his then-outstanding equity awards granted by the Company will be fully vested. Dr. Jun Pei’s right to receive these severance benefits is subject to his providing a release of claims to the Company and his continued compliance with his confidentiality, non-solicitation and other covenants in favor of the Company.

The agreements for Mr. Hull Xu and Dr. Liqun Han each provide the executive will receive an initial annual base salary of $280,000 and is eligible for an annual discretionary bonus as determined by the Compensation Committee and to participate in the Company’s benefit plans made available to employees generally. If the executive’s employment with the Company is terminated by the Company without “cause” or by the executive for “good reason” (as defined in the agreement), the executive will receive severance of 12 months base salary, payable in installments over a 12-month period, payment of his COBRA premiums for 12 months, and 12 months’ accelerated vesting of his then-outstanding and unvested equity awards granted by the Company. However, if such a termination of the executive’s employment occurs in connection with or within 18 months following a change in control of the Company, the executive’s severance will equal the sum of 12 months of his base salary and his annual target bonus for the year of termination (or, if no target bonus has been established, the amount of his actual bonus for the prior year) and will be paid in a lump sum, and his then-outstanding equity awards granted by the Company will be fully vested. In each case, the executive’s right to receive these severance benefits is subject to his providing a release of claims to the Company and his continued compliance with his confidentiality, non-solicitation and other covenants in favor of the Company.

Defined Contribution Plans

As part of our overall compensation program, we provide all full-time employees, including each of our NEOs, with the opportunity to participate in a defined contribution 401(k) plan. Our 401(k) plan is intended to qualify under Section 401 of the Internal Revenue Code so that employee contributions and income earned on such contributions are not taxable to employees until withdrawn. Employees may elect to defer a percentage of their eligible compensation (not to exceed the statutorily prescribed annual limit) in the form of elective deferral contributions to the plan. Our 401(k) plan also has a “catch-up contribution” feature for employees aged 50 or older (including those who qualify as “highly compensated” employees) who can defer amounts over the statutory limit that applies to all other employees. The Company does not currently make any matching or other contributions to participants’ accounts under the 401(k) plan.

CEPTON, INC.

2023 PROXY STATEMENT

21

COMPENSATION COMMITTEE INTERLOCKS AND
INSIDER PARTICIPATIO
N

Dr. Jun Ye, Dr. Mei (May) Wang and Mr. George Syllantavos served as members of our Compensation Committee during all of fiscal 2022. None of the members of our Compensation Committee during fiscal 2022 was or is an officer or employee of our Company. None of our executive officers currently serves, or in the past year has served, as a member of the Board or Compensation Committee (or other Board committee performing equivalent functions) of any entity that has one or more of its executive officers serving on our Board or Compensation Committee.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMEN
T

The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 1,June 30, 2023 for:

        each of our named executive officers;

        each of our directors;

        all of our current directors and executive officers as a group; and

        each person known by us to be the beneficial owner of more than 5% of the outstanding shares of our common stock.

We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections 13(d) and 13(g) of the Securities Act.

We have based our calculation of the percentage of beneficial ownership on 156,761,170158,224,189 shares of our common stock outstanding as of March 1,June 30, 2023. In accordance with SEC rules, we have deemed shares of our common stock subject to stock options or warrants that are currently exercisable or exercisable within sixty (60) days of March 1,June 30, 2023 and shares of our common stock underlying RSUs that are currently releasable or releasable within sixty (60) days of March 1,June 30, 2023 to be outstanding and to be beneficially owned by the person holding the common stock, options, warrants or RSUs for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.

Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Cepton, Inc., 399 West Trimble Road, San Jose, California, 95131. The information provided in the table is based on our records, information filed with the SEC and information provided to us, except where otherwise noted.

Name and Address of Beneficial Owner

 

Number of Shares of Common Stock Beneficially Owned

 

%

5% Holders:

    

 

Koito Manufacturing Co., Ltd.(1)

 

19,624,741

 

12.4

%

LDV Partners Fund I, L.P.(2)

 

16,163,422

 

10.2

%

Dr. Mark McCord(3)

 

10,389,248

 

6.6

%

Yupeng Cui(4)

 

9,679,376

 

6.1

%

Executive Officers and Directors:

    

 

Dr. Jun Pei(5)

 

27,238,261

 

17.2

%

Dr. Jun Ye(6)

 

25,916,966

 

16.4

%

Hull Xu(7)

 

543,953

 

*

 

Dr. Liqun Han(8)

 

3,017,686

 

1.9

%

Dr. Dongyi Liao(9)

 

2,472,694

 

1.6

%

George Syllantavos(10)

 

1,053,423

 

*

 

Takayuki Katsuda(11)

 

 

%

Hideharu (Harry) Konagaya(12)

 

 

%

Dr. Mei (May) Wang

 

76,923

 

*

 

Xiaogang (Jason) Zhang

 

76,923

 

*

 

Directors and executive officers as a group (ten individuals)

 

60,396,829

 

38.2

%

____________

22

2023 PROXY STATEMENT

CEPTON, INC.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Name and Address of Beneficial Owners

 

Number of Shares
of
common stock
Beneficially Owned

 

%

5% Holders:

    

 

Koito Manufacturing Co., Ltd.(1)

 

19,624,741

 

12.5

%

LDV Partners Fund I, L.P.(2)

 

16,163,422

 

10.3

%

Yupeng Cui(3)

 

9,679,376

 

6.2

%

Executive Officers and Directors:

    

 

Dr. Jun Pei(4)

 

29,178,885

 

18.6

%

Dr. Jun Ye(5)

 

25,916,966

 

16.5

%

Hull Xu(6)

 

331,416

 

*

 

Dr. Mark McCord(7)

 

10,389,248

 

6.6

%

Dr. Liqun Han(8)

 

2,847,237

 

1.8

%

Dr. Dongyi Liao(9)

 

2,308,912

 

1.5

%

George Syllantavos(10)

 

976,500

 

*

 

Takayuki Katsuda(11)

 

 

 

Hideharu (Harry) Konagaya(12)

 

 

 

Dr. Mei (May) Wang

 

 

 

Xiaogang (Jason) Zhang

 

 

 

Directors and executive officers as a group (eleven individuals)

 

71,949,164

 

45.0

%

*        Less than one percent.1% of outstanding common stock.

(1)      Consists of 19,624,741shares of common stock. The business address of Koito Manufacturing Co., Ltd. is 5-1-18, Kitashinagawa, Shinagawa-ku, Tokyo, Japan.

15

Table of Contents

(2)      Based on Amendment No. 1 to the Schedule 13G filed by LDV Partners Fund I, L.P. on February 6, 2023.

(3)      Consists of 10,389,248 shares of common stock owned by the McCord Trust, dated January 7, 2020, of which Dr. McCord is a trustee.

(4)      Consists of 9,679,376shares of common stock.

(4)(5)      Consists of 1,224,6171,283,993 shares of common stock owned by Dr. Pei and 27,954,26825,954,268 shares of common stock owned by the Pei 2000 Trust of which Dr. Pei is a trustee.

(5)(6)      Consists of (i) 20,818,496shares of common stock owned by Dr. Ye; (ii) 2,449,235shares of common stock owned by the Lynnelle Lin Ye Irrevocable Trust dated December 8, 2020 of which Dr. Ye is a trustee; (iii) 2,449,235 shares of common stock owned by the Brion Qi Ye Irrevocable Trust dated December 8, 2020 of which Dr. Ye is a trustee; (iv) and 200,000 shares of common stock owned by the Ye-Wang Family Trust, dated March 31, 2007, of which Dr. Ye is a trustee.

(6)(7)      Consists of (i) 318,916395,454 shares of common stock issuable pursuant to options exercisable within 60 days of June 30, 2023; (ii) 135,999 shares of common stock owned by Mr. Xu; and (ii)(iii) 12,500shares of common stock issuable pursuant to warrants in each case, exercisable within 60 days of March 1,June 30, 2023.

(7)      Consists of 10,389,248shares of common stock owned by the McCord Trust, dated January 7, 2020, of which Dr. McCord is a trustee. On March 14, 2023, Mr. McCord transitioned to the chair of our Technology Advisory Board and ceased to be an executive officer.

(8)      Consists of 489,847shares of common stock owned by The Han-Ouyang Living Trust, U/A, dated March 21, 2021, of which Dr. Han is a trustee, and 2,357,3902,418,619 shares of common stock issuable pursuant to options exercisable within 60 days of March 1,June 30, 2023.

(9)      Consists of 2,308,912(i) 100,000 shares of common stock owned by Dr. Liao and (ii) 2,372,694 shares of common stock issuable pursuant to options exercisable within 60 days of March 1,June 30, 2023.

(10)    Consists of 359,000435,923 shares of common stock owned by Mr. Syllantavos and 617,500shares of common stock issuable to Magellan Investments Corp. pursuant to warrants that are exercisable within 60 days of March 1,the date June 30, 2023. Mr. Syllantavos is the president and the sole director of Magellan Investments Corp.

(11)    Mr. Katsuda is the Managing Corporate Officer of Koito Manufacturing Co., Ltd. The business address of Mr. Katsuda is c/c/o Koito Manufacturing Co., Ltd., 5-1-18, Kitashinagawa, Shinagawa-ku, Tokyo, Japan.

(12)    Mr. Konagaya is a Senior Managing Director, Head of the Finance & Accounting Department, and Head of the Procurement Department of Koito Manufacturing Co., Ltd. The business address of Mr. Konagaya is c/c/o Koito Manufacturing Co., Ltd., 5-1-18, Kitashinagawa, Shinagawa-ku, Tokyo, Japan.

16

Table of Contents

WHERE YOU CAN FIND MORE INFORMATION

CEPTON, INC.

2023 PROXY STATEMENT

23

EQUITY INCENTIVE PLAN INFORMATION

We currently maintain three equity incentive plans — our 2022 Plan, our Employee Stock Purchase Plan (the “ESPP”),The Company files annual, quarterly and our Stock Incentive Plan (the “2016 Plan”). Each of these plans has been approved by our stockholders.current reports, proxy statements and other information with the SEC. The table below presentsSEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the numberSEC, including us. The address of outstanding awards and shares available for issuance under these plans as of December 31, 2022.

Plan category

 

(a) 
Number of Securities
to be Issued
Upon Exercise
of Outstanding
Options, Warrants
and Rights

 

(b) 
Weighted-Average
Exercise Price of
Outstanding
Options, Warrants
and Rights ($)

 

(c) 
Number of Securities
Remaining Available for Future Issuance
Under Equity
Compensation Plans
(Excluding Securities
Reflected in Column
(a))

Equity compensation plans approved by security holders

 

19,093,676

(1)

 

2.14

(2)

 

13,477,760

(3)

Equity compensation plans not approved by security holders

 

 

 

 

 

 

Total

 

19,093,676

 

 

2.14

 

 

13,477,760

 

that site is (1)      Of these shares, 4,831,692www.sec.govshares were subject to outstanding awards of RSUs (including stock units subject to performance-based vesting) granted under the 2022 Plan, 524,050shares were subject to outstanding options granted under the 2022 Plan, and 13,737,934shares were subject to outstanding awards granted under the 2016 Plan..

(2)      This figure does not take into account outstanding awards of RSUs.

(3)      Of these shares, 10,396,800shares were available for issuance under the 2022 Plan, and 3,080,960shares were available for issuance under the ESPP. The shares available for issuance under the 2022 Plan are generally available for any type of award authorized under that plan, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other awards. No new awards may be granted under the 2016 Plan. The Company has not yet implemented the ESPP, and no shares have been issued under that plan.

24

2023 PROXY STATEMENT

CEPTON, INC.

REPORT OF AUDIT COMMITTEE

The Audit Committee assists the Board in its oversight ofYou can also review the Company’s financial statements and reporting process, audit process and internal controls. The Audit Committee operates under a written charter adopted bySEC filings on its website at http://investors.cepton.com. Through links on the Board, which describes this and the other responsibilities of the Audit Committee. Management has the primary responsibility for the financial statements and the reporting process, including the systems of internal controls. Our independent registered public accounting firm is responsible for performing an independent audit“Investors” portion of our consolidated financial statements and effectivenesswebsite, we make available free of internal control over financial reporting in accordance with the auditing standards of the Public Company Accounting Oversight Board (“PCAOB”) and to issue a report thereon.

The Audit Committee has reviewed and discussed the Company’s audited financial statements with management, which has primary responsibility for the financial statements. KPMG LLP, the Company’s independent registered public accounting firm for fiscal 2022, is responsible for expressing an opinion on the conformity of the Company’s audited financial statements with generally accepted accounting principles and the effectiveness of its internal control over financial reporting. The Audit Committee has discussed with KPMG LLP the matters required to be discussed by the applicable requirements of the PCAOB and SEC. The Audit Committee has received and reviewed the written disclosures and the letter from KPMG LLP required by applicable requirements of the PCAOB regarding KPMG LLP’s communications with the Audit Committee concerning independence, and has discussed with KPMG LLP its independence.

Based on the review and discussions referred to above, the Audit Committee recommended to the Board that the audited financial statements be included in the Company’s 2022charge our Annual Report on Form 10-K for filing, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, any amendments to those reports and other information filed with, or furnished to, the SEC pursuant to Sections 13(a) or 15(d) of the Exchange Act. Such material is made available through our website as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC. The Audit Committee also appointed KPMG LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 and is seeking ratification of such selection by the Company’s stockholders at the Annual Meeting.

AUDIT COMMITTEE
George Syllantavos (Chair)
Xiaogang (Jason) Zhang
Dr. Mei (May) Wang

April 6, 2023

The foregoing report of the Audit Committeeinformation contained on or that can be accessed through our website does not constitute soliciting material and shall not be deemed filed, incorporated by reference into or a part of any other filing by the Company (including any future filings) under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934 (the “Exchange Act”), except to the extent the Company specifically incorporates such report by reference therein.

CEPTON, INC.

2023 PROXY STATEMENT

25

PROPOSAL 2 — RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR 2023. UNLESS OTHERWISE INSTRUCTED, THE PROXY HOLDERS WILL VOTE THE PROXIES RECEIVED BY THEM “FOR” RATIFICATION OF THE APPOINTMENT OF KPMG LLP.

The Audit Committee of our Board has appointed KPMG LLP to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023. We are not required to submit the appointment of KPMG LLP for stockholder approval, but our Board has elected to seek ratification of the appointment of our independent registered public accounting firm by the affirmative vote of a majority of the shares present or represented by proxy and entitled to vote on the proposal at the Annual Meeting. If our stockholders do not ratify the appointment of KPMG LLP, the Audit Committee will reconsider its appointment of KPMG LLP and will either continue to retain this firm or appoint a new independent registered public accounting firm. Even if the appointment is ratified, the Audit Committee, in its discretion, may appoint a different independent registered public accounting firm at any time during the year if the Audit Committee determines that such a change would be in our best interests and the best interests of our stockholders.

We expect one or more representatives of KPMG LLP to participate in the Annual Meeting and they will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

The aggregate fees billed to us for the fiscal year ended December 31, 2022 and 2021 by our independent registered public accounting firm, KPMG LLP, are as follows:

   

2022

 

2021

  
  

Audit Fees(1)

 

$

680,000

 

$

1,175,000

  
  

Audit-Related Fees

 

 

 

 

  
  

Tax Fees

 

 

 

 

  
  

All Other Fees

 

 

 

 

  
  

Total Fees

 

$

680,000

 

$

1,175,000

  

(1)      Audit Fees represent the aggregate fees billed to us by KPMG LLP for professional services rendered for the audit of our annual consolidated financial statements for the fiscal year ended December 31, 2022, for the reviews of our consolidated financial statements included in our Form 10-Q filings for each fiscal quarter since the Business Combination in February 2022, and for procedures performed with respect to registration statements.

Audit Committee Pre-Approval Policies and Procedures

The Audit Committee is required to pre-approve the audit and non-audit services performed by our independent registered public accounting firm in order to assure that the provision of such services does not impair the auditor’s independence. The Audit Committee at least annually reviews and provides general pre-approval for the services that may be provided by the independent registered public accounting firm.

All services performed and related fees billed by KPMG LLP during fiscal 2022 and fiscal 2021 were pre-approved by the Audit Committee pursuant to the foregoing pre-approval policy of the Audit Committee.

26

2023 PROXY STATEMENT

CEPTON, INC.

TRANSACTIONS WITH RELATED PERSONS

Policies and Procedures Regarding Related Party Transactions

Our Board has adopted a written Related Person Transactions Policy that sets forth the Company’s policies and procedures regarding the identification, review, consideration and oversight of “related person transactions.” For purposes of our policy, a “related person transaction” is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which (i) the Company (including any of its subsidiaries) was, is or will be a participant, (ii) the aggregate amount involved exceeds or may be expected to exceed $120,000 and (iii) a related person has or will have a direct or indirect material interest.

Subject to certain limitations, transactions involving compensation for services provided to the Company as an employee or director will not be considered related person transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of any class of our voting securities (including the common stock), including any of their immediate family members and affiliates, including entities owned or controlled by such persons. A related person is also someone who has a position or relationship with any firm, corporation or other entity that engages in the transaction if (i) such person is employed or is a general partner or principal or in a similar position with significant decision making influence, or (ii) the direct or indirect ownership by such person and all other foregoing persons, in the aggregate, is 10% or greater in another person which is party to the transaction.

Under the policy, any related person, or any director, officer or employee of the Company who knows of the transaction, must report the information regarding the proposed related person transaction to our Chief Financial Officer and chairperson of the Audit Committee for review. To identify related person transactions in advance, we will rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related person transactions, the Audit Committee will take into account the relevant available facts and circumstances, which may include, but are not limited to:

●      the nature of the related person’s interest in the transaction;

●      the impact on a director’s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;

●      the terms of the transaction;

●      the availability of other sources for comparable services or products; and

●      the terms available to or from, as the case may be, unrelated third parties.

All related party transactions may be consummated or continued only if approved or ratified by our Audit Committee. No director or member of our Audit Committee may participate in the review, approval or ratification of a transaction with respect to which he or she is a related party, except that such member may be counted for purposes of a quorum and shall provide such information with respect to the transaction as may be reasonably requested by other members of our Audit Committee.

Certain Relations and Related Party Transactions

Investment Agreement

On October 27, 2022, the Company entered into an Investment Agreement (the “Investment Agreement”) with Koito, pursuant to which, among other things, at the closing of the transactions, and based on the terms and subject to the conditions set forth therein, the Company issued and sold to Koito, 100,000 shares of Series A Convertible Preferred Stock, par value $0.00001 per share (the “Preferred Stock”) for a purchase price of $100.0 million (the “Transaction”). The Preferred Stock will be convertible, beginning on January 19, 2024, into shares of the

CEPTON, INC.

2023 PROXY STATEMENT

27

TRANSACTIONS WITH RELATED PERSONS

Company’s common stock at an approximate initial conversion price of $2.585 per share (subject to adjustment). The issuance and sale of the Preferred Stock and related matters were approved by the Company’s stockholders on January 11, 2023, and the Preferred Stock was issued to Koito on January 19, 2023.

Investor Rights Agreement

Board and Committee Rights

At the closing of the issuance of the Preferred Stock, the Company and Koito entered into an Investor Rights Agreement (the “Investor Rights Agreement”), pursuant to which, among other things, the Company ensured that two designees of Koito (Mr. Takayuki Katsuda and Mr. Hideharu (Harry) Konagaya) sat on the Board immediately following the closing. Koito is entitled to have its designees appointed to the Nominating and Corporate Governance Committee and Compensation Committee of the Company’s Board, subject to satisfaction of applicable committee membership requirements. Furthermore, under the Investor Rights Agreement, the Company is obligated to take all necessary action (to the extent not prohibited by law) to cause the Board to nominate for election that number of individuals designated by Koito that is proportional to Koito’s beneficial ownership interest in the Company, provided, however, that Koito will not be entitled to nominate for election a number of individuals that would constitute a majority of the Board. In addition, Koito’s designation rights will be reduced to one director at such time as Koito ceases to beneficially own at least 10% of the outstanding shares of common stock (on an as-converted basis) and Koito will no longer have any rights to designate a nominee to serve on the Board at such time as Koito ceases to beneficially own at least 5% of the outstanding shares of common stock (on an as-converted basis).

Investor Consent Rights

Pursuant to the terms of the Investor Rights Agreement, the prior written consent of Koito (the “Investor Consent Rights”) is required for the Company to effect or validate certain enumerated actions in the Investor Rights Agreement for so long as Koito beneficially owns a number of shares of common stock representing at least 75% of the number of shares of common stock held by Koito as of the closing date after giving effect to the Transaction and including the shares of common stock issuable upon conversion of the Preferred Stock, including, but not limited to: (i) issuing securities that are senior or pari passu to the Preferred Stock, (ii) declaring or paying dividends, (iii) acquiring, redeeming or repurchasing capital stock, (iv) incurring debt or liens for borrowed money in excess of specified amounts, (v) entering into related party transactions, (vi) amending the Company’s charter or bylaws, (vii) changing the size of the Board, (viii) adopting a poison pill (unless it grandfathers in Koito), (ix) making acquisitions in excess of specified amounts, (x) selling, leasing or transferring assets or properties, or incurring liens (other than certain permitted liens) in excess of specified amounts, (xi) increasing the number of shares reserved for issuance under the Company’s existing equity incentive plans beyond automatic annual increases currently provided for under such plans, (xii) transfers or abandonment of, or incurrence of liens on, the Company’s material intellectual property and (xiii) capital expenditures in excess of specified amounts.

Preemptive Rights

Pursuant to the terms of the Investor Rights Agreement, and subject to certain exceptions, when the Company authorizes the issuance or sale of any common stock or equity-linked securities (as defined in the Investor Rights Agreement), the Company is required to first offer to sell to Koito a proportion of such common stock or equity-linked securities sufficient for Koito to maintain its pro rata share in the common stock (on an as-converted, exchanged or exercised basis, as applicable) prior to the issuance or sale of such common stock or equity-linked securities to such other person, with the consummation of the sale or issuance to such other person and to Koito to occur on the same date, subject to certain exceptions.

28

2023 PROXY STATEMENT

CEPTON, INC.

TRANSACTIONS WITH RELATED PERSONS

Registration Rights

Pursuant to the Investor Rights Agreement, among other things, and subject to certain limitations set forth therein, the Company is obligated to prepare and file within 300 days after January 19, 2023 a registration statement registering shares of common stock held by any holder of Preferred Stock, including any shares of common stock acquired by any holder pursuant to the conversion of, or as a dividend on, the Preferred Stock (the “Registrable Securities”).

In addition, pursuant to the Investor Rights Agreement, holders of Registrable Securities have the right to require the Company, subject to certain limitations set forth therein, to effect a sale of any or all of their Registrable Securities by means of an underwritten offering. The Company is not obligated to effect an underwritten offering (a) more than twice in any 365-day period, (b) if the anticipated gross proceeds are less than $25 million (unless Koito is proposing to sell all of its remaining Registrable Securities), or (c) during a Quarterly Blackout Period (as defined in the Investor Rights Agreement).

The Investor Rights Agreement also provides holders of Registrable Securities with certain customary piggyback registration rights and indemnification rights.

These registration rights are subject to certain conditions and limitations, including the right of the underwriters to limit the number of shares to be included in a registration or offering and the Company’s right to delay or withdraw a registration statement under certain circumstances.

Termination

The Investor Rights Agreement will terminate with respect to Koito upon the mutual agreement in writing among the Company and Koito, other than termination provisions applicable to particular sections of the Investor Rights Agreement that are specifically provided in the Investor Rights Agreement. The Investor Rights Agreement will terminate automatically with respect to any other party thereto at such time as such party ceases to own any Registrable Securities.

The foregoing summary of the Investor Rights Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, the full text of the Investor Rights Agreement, which was included as an exhibit to our annual report on Form 10-K for 2022, filed with the SEC on March 20, 2023.

Secured Term Loan Agreement with Koito

Concurrently with the execution of the Investment Agreement, the Company entered into a Secured Term Loan Agreement with Koito (the “Secured Term Loan Agreement”) to borrow Japanese Yen ¥5.8 billion (approximately $39.4 million). The borrowings under the Secured Term Loan Agreement (the “Loan”) accrued interest at a rate equal to 1.0% per annum, which was payable at maturity. The Loan was set to mature on the earlier of three business days after the closing of the transactions contemplated by the Investment Agreement and the date on which the Investment Agreement was terminated in accordance with its terms. The Secured Term Loan Agreement entered into with Koito is a related party transaction issued at below market interest rates. On November 7, 2022, the Company borrowed ¥5.8 billion under the agreement. To reflect what a similar debt instrument would be issued at with market interest rate, the Company recorded a $2.0 million debt discount accounted for as a capital contribution within additional paid-in capital in the consolidated balance sheet. Amortization of debt discounts, in accordance with the effective interest method, are recorded as interest expense in the accompanying consolidated statement of operations and comprehensive income (loss). Obligations under the Secured Term Loan Agreement were secured by interest in substantially all of the Company’s assets, including all patents.

The agreement contained customary affirmative and negative covenants. On January 24, 2023, the Company used the proceeds from the sale of the Preferred Stock to repay all outstanding principal and accrued interest under the Secured Term Loan Agreement with Koito. See Note 21 of the consolidated financial statements in our annual report on Form 10-K for 2022, filed with the SEC on March 20, 2023, for further information.

CEPTON, INC.

2023 PROXY STATEMENT

29

TRANSACTIONS WITH RELATED PERSONS

For the year ended December 31, 2022, the Company recognized $0.8 million in interest expense in connection with the borrowings under the Secured Term Loan Agreement with Koito. Additionally, the Company recognized a $4.3 million foreign currency transaction loss on remeasurement using the applicable exchange rate on December 31, 2022.

Transactions with Koito

Koito is an automotive tier 1 partner of the Company and sales to Koito accounted for 43% of our total revenues for the year ended December 31, 2022. In 2020, the Company was chosen by Koito to supply Koito with advanced driver assistance systems (“ADAS”) lidar technology licenses and components for General Motors’ ADAS series production program for mass-market consumer vehicles. The purpose of the arrangement is to supply Koito with automotive grade lidars using the Company’s components and lidar technology. These lidars are to be supplied to General Motors to fulfill the needs of its series production program. Production volume will ultimately be dependent on numerous factors and are binding only upon issuance of a purchase order. Revenue generated from Koito was $3.2 million and $3.1 million for the years ended December 31, 2022 and 2021, respectively. Accounts receivable from Koito was $1.0 million as of December 31, 2022 and was $0.1 million as of December 31, 2021.

Other

Dr. Jun Pei’s wife, Yiyan Liu, is employed by the Company in a non-executive position and her overall compensation, including salary, bonus and other benefits, for 2022 did not exceed $180,000.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires the Company’s executive officers and directors, and persons who own more than ten percent of a registered class of the Company’s equity securities, to file initial reports of ownership on Form 3 and changes in ownership on Form 4 or Form 5 with the SEC. Based on a review of the Company’s records and other information, the Company believes that all Section 16(a) filing requirements were met during fiscal 2022. On February 8, 2023, Dr. Jun Pei’s wife, Yiyan Liu, received an award of 71,154 time-based RSUs. A Form 4 reporting Dr. Pei’s interest this transaction was filed with the SEC on February 15, 2023.

30

2023 PROXY STATEMENT

CEPTON, INC.

PROPOSALS OF STOCKHOLDERS AND DIRECTOR
NOMINATIONS FOR 2024 ANNUAL MEETIN
G

Requirements for Proposals to be Considered for Inclusion in Proxy Materials. For your proposal to be considered for inclusion in the proxy statement for our 2024 annual meeting of stockholders, your written proposal must be received by our Corporate Secretary at our principal executive offices no later than December 8, 2023. and must comply with Rule 14a-8 under the Exchange Act regarding the inclusion of stockholder proposals in Company-sponsored proxy materials. If we change the date of the 2024 annual meeting of stockholders by more than 30 days from the anniversary of this year’s Annual Meeting, your written proposal must be received within a reasonable time before we begin to print and mail our proxy materials for the 2024 annual meeting of stockholders.Statement.

Nominations of Director Candidates and Proposals Not Intended for Inclusion in Proxy Materials. If you intend to nominate an individual for election to our Board at our 2024 annual meeting of stockholders or wish to present a proposal at the 2024 annual meeting of stockholders but do not intend for such proposal to be included in the proxy statement for such meeting, our Bylaws require that, among other things, stockholders give written notice of the nomination or proposal to our Corporate Secretary at our principal executive offices no later than February 18, 2024 (the 90th day before the first anniversary of the date of the preceding year’s annual meeting) nor earlier than January 19, 2024 (the 120th day before the first anniversary of the date of the preceding year’s annual meeting) for the Annual Meeting. Notwithstanding the foregoing, in the event that we change the date of the 2024 annual meeting of stockholders to a date that is more than 30 days before or more than 70 days after the anniversary of the Annual Meeting, than the ninetieth (90th) day prior to such annual meeting or, if later, the tenth (10th) day following the day on which public announcement of the date of such annual meeting was first made. Stockholder proposals not intended to be included in the proxy statement or nominations for director candidates that do not meet the notice requirements set forth above and further described in Section 2.4 of our Bylaws will not be acted upon at the 2024 annual meeting of stockholders.

In addition, a stockholder who intends to solicit proxies in support of director nominees other than the Company’s nominees at the 2024 annual meeting of stockholders must provide written notice to our Corporate Secretary setting forth the information required by Rule 14a-19 under the Exchange Act, unless the required information has been provided in a preliminary or definitive proxy statement previously filed by the stockholder. Such written notice must be provided in accordance with Rule 14a-19 no later than March 19, 2024. If we change the date of the 2024 annual meeting of stockholders by more than 30 days from the date of this year’s annual meeting, your written notice must be received by the later of 60 days prior to the date of the 2024 annual meeting of stockholders or the 10th calendar day following the day on which public announcement of the date of the 2024 annual meeting of stockholders is first made. The notice requirement under Rule 14a-19 is in addition to the applicable notice requirements under our Bylaws as noted above.

CEPTON, INC.

2023 PROXY STATEMENT

31

OTHER MATTERS

We do not know of any other matter that will be brought before the AnnualSpecial Meeting. However, if any other matter properly comes before the AnnualSpecial Meeting or any adjournment(s)postponement(s) or postponement(s)adjournment(s) thereof, which may properly be acted upon, the proxyholders named in the proxies solicited by the Board will have the authority to vote all proxies received with respect to such matters in their discretion, and it is their intention to vote such proxies in accordance with the recommendation of the Board.

As permitted by the Exchange Act, only one copy of our proxy materials is being delivered to stockholders of record residing at the same address unless such stockholders have notified us of their desire to receive multiple copies of our proxy materials. This is known as householding. We will promptly deliver, upon oral or written request, a separate copy of the proxy materials to any stockholder residing at an address to which only one copy was mailed. Stockholders who currently receive multiple copies of proxy materials at their address and would like to request householding of their communications should contact us. Requests for additional copies or requests for householding for this year or future years should be directed in writing to Householding Department of Broadridge Financial Solutions, Inc. at 51 Mercedes Way, Edgewood, New York 11717, or at 1-866-540-7095.

ANNUAL REPORT TO STOCKHOLDERS

17

Table of Contents

QUESTIONS AND ANSWERS ABOUT THE PROXY
MATERIALS AND Special MEETING

Our 2022 Annual Report on Form 10-K for the year ended December 31, 2022 (the 2022 Annual Report”) has been posted on our corporate website at https://investors.cepton.com/ and on the Internet at www.cstproxyvote.com. Stockholders receiving a printed copy of this Proxy Statement have also received a copy of our 2022 Annual Report. We will provide, without charge, a copy of our 2022 Annual Report for the fiscal year ended December 31, 2022 (including the financial statements but excluding the exhibits thereto) upon the written request of any stockholder or beneficial owner of our common stock. Requests should be directed to our Corporate Secretary at the following address:

Cepton, Inc.
399 West Trimble Road
San Jose, California 95131

32

2023 PROXY STATEMENT

CEPTON, INC.

QUESTIONS AND ANSWERS ABOUT THE PROXY
MATERIALS AND ANNUAL MEETIN
G

In accordance with rules and regulations adopted by the SEC, we have elected to provide access to our proxy materials by sending you this full set of proxy materials, including a proxy card. Accordingly, the Proxy Statement and accompanying proxy card will first be mailed to our stockholders on or about April 6,August 8, 2023.

What items of business will be voted on at the Annual

What items of business will be voted on at the Special Meeting?

The items of business scheduled to be voted on at the AnnualSpecial Meeting are:

1.     The election of the three Class A director nominees named in this Proxy Statement to serve until our 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified (“Proposal 1”); and

2.     The ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2023 (“Proposal 2”).

Proposal One.

Approve a series of sixteen alternative potential amendments to the Company’s Second Amended and Restated Certificate of Incorporation to authorize the Company’s Board of Directors to effect (i) a reverse stock split of the issued shares of our common stock (including shares of common stock held by the Company in treasury), at ratios of 1 share of common stock for each whole number of issued shares of our common stock between five and twenty, which ratio to become effective to be determined by the Board of Directors if the Board of Directors subsequently determines to proceed with the reverse stock split, and (ii) a corresponding reduction in the total number of authorized shares of common stock and corresponding reduction in the total number of shares the Company is authorized to issue; and

Proposal Two.

Adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve Proposal One.

Stockholders will also be asked to consider and transact such other business as may properly come before the AnnualSpecial Meeting or any postponement or adjournment of the meeting.

How does the Board of Directors recommend I vote on these proposals?

Our Board recommends that you vote your shares:

1.      “FOR ALL”“FOR” Proposal One: the approval of a series of sixteen alternative potential amendments to the Company’s Second Amended and Restated Certificate of Incorporation to authorize the Company’s Board of Directors to effect (i) a reverse stock split of the following director nominees namedissued shares of our common stock (including shares of common stock held by the Company in this Proxy Statementtreasury), at ratios of 1 share of common stock for each whole number of issued shares of our common stock between five and twenty, which ratio to become effective to be electeddetermined by the Board of Directors if the Board of Directors subsequently determines to proceed with the Board: Dr. Jun Ye, Dr. Mei (May) Wangreverse stock split, and Mr. Hideharu (Harry) Konagaya;(ii) a corresponding reduction in the total number of authorized shares of common stock and corresponding reduction in the total number of shares the Company is authorized to issue; and

2.      “FOR” Proposal Two: the ratificationadjournment of the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2023.Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to approve Proposal One.

Who is entitled to vote?

Only stockholders of record at the close of business on March 20,July 28, 2023 (the “Record Date”Record Date) will be entitled to notice of and to vote at the AnnualSpecial Meeting. As of the Record Date, there were 156,826,093158,224,189 shares of our common stock outstanding and entitled to vote at the AnnualSpecial Meeting.

What is the difference between a “beneficial owner” and a “stockholder of record”?

Whether you are a “beneficial owner” or a “stockholder of record” with respect to your shares depends on how you hold your shares:

        Beneficial Owners.    Most of our stockholders hold their shares through a broker, bank, or other nominee (that is, in “street name”) rather than directly in their own names. If you hold shares in street name, you are a “beneficial owner” of those shares, and the proxy materials, together with a voting instruction form, will be forwarded to you by your broker, bank or other nominee.

18

Table of Contents

        Stockholders of Record.    If you hold shares directly in your name with our stock transfer agent, Continental Stock Transfer & Trust Company, you are considered the “stockholder of record” with respect to those shares, and the proxy materials, together with a proxy card, have been sent directly to you by the Company.

CEPTON, INC.

2023 PROXY STATEMENT

33

QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND ANNUAL MEETING

Can I attend the AnnualCan I attend the Special Meeting?

We will be hosting the AnnualSpecial Meeting live via the Internet. You will not be able to attend the AnnualSpecial Meeting in person.person. Any stockholder can listen to and participate in the AnnualSpecial Meeting live via the Internet at https://www.cstproxy.com/cepton/am2023,sm2023, and can also be accessed by phone at +1 8001-450-7155-800-450-7155 (toll-free) (within the U.S. and Canada) or +1 8571-999-9155-857-999-9155 (standard rates apply) (outside of the U.S. and Canada). The conference ID for the meeting is 8384705#. Our Board annually considers the appropriate format of our annual meeting.3127195#. Our virtual annual meetingSpecial Meeting allows stockholders to submit questions and comments before and during the meeting. After all proposals are presented at the meeting, we will spend up to 15 minutes answering stockholder questions that comply with the meeting rules of conduct, which will be posted on the virtual meeting web portal. To the extent time doesn’t allow us to answer all of the appropriately submitted questions, we will answer them in writing on our investor relations website, at https://investors.cepton.com/, soon after the meeting. If we receive substantially similar questions, we will group such questions together and provide a single response to avoid repetition.

The AnnualSpecial Meeting webcast will begin promptly at 9:00 a.m., Pacific Time. We encourage you to access the AnnualSpecial Meeting webcast prior to the start time. Online check-in will begin, and stockholders may begin submitting written questions, at 8:45 a.m., Pacific Time, and you should allow ample time for the check-in procedures.

What do I need in order to be able to participate in the Annual

What do I need in order to be able to participate in the Special Meeting?

You will need the control number included on your proxy card or voting instruction form in order to be able to vote your shares or submit questions during the AnnualSpecial Meeting. If you do not have your control number, you will be able to access and listen to the AnnualSpecial Meeting, but you will not be able to vote your shares or submit questions during the Annual MeetingSpecial Meeting..

We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting or submitting questions. If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the log in page at https://www.cstproxy.com/cepton/am2023.sm2023.

Why is the Company holding the Annual

Why is the Company holding the Special Meeting virtually?

We are embracing technology to provide expanded access, improved communication, reduced environmental impact and cost savings for our stockholders and the Company. Hosting a virtual meeting enables increased stockholder attendance and participation since stockholders can participate and ask questions from any location around the world and provides us an opportunity to give thoughtful responses. In addition, we intend the virtual meeting format to provide stockholders with a similar level of transparency to the traditional in-person meeting format, and we take steps to ensure such an experience. Our stockholders will be afforded the same opportunities to participate at the virtual AnnualSpecial Meeting as they would at an in-person annual meeting of stockholders.meeting.

How do I vote and what are the voting deadlines?

●      How do I vote and what are the voting deadlines?

•        Beneficial Owners.    If you are a beneficial owner of your shares, you should have received the proxy materials and voting instruction form from the broker, bank or other nominee holding your shares. You should follow the instructions in the voting instruction form in order to instruct your broker, bank or other nominee on how to vote your shares. The availability of telephone and Internet voting will depend on the voting process of the broker, bank or nominee. You may also vote your shares while participating in the AnnualSpecial Meeting. Instructions on how to vote while participating in the AnnualSpecial Meeting live via the Internet are posted at https://www.cstproxy.com/cepton/am2023.sm2023.

        Stockholders of Record.    If you are a stockholder of record, there are several ways to direct how your shares are voted at the AnnualSpecial Meeting.

Via the Internet.    You may submit a proxy over the Internet at https://www.cstproxyvote.com, 24 hours a day, seven days a week. You will need the control number included on your proxy card. Proxies submitted through the Internet must be received by 11:59 p.m., Eastern Time, on May 17,September 6, 2023.

34

19

Table of Contents

2023 PROXY STATEMENT

CEPTON, INC.

QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND ANNUAL MEETING

By TelephoneTelephone..    You may submit a proxy using a touch-tone telephone by calling 1-866-894-0536, 24 hours a day, seven days a week. You will need the control number included on your proxy card. Proxies submitted by telephone must be received by 11:59 p.m., Eastern Time, on May 17,September 6, 2023.

By MailMail..    You may direct how your shares are voted at the AnnualSpecial Meeting by completing, signing and dating each proxy card received and returning it in the prepaid envelope. Sign your name exactly as it appears on the proxy card. Proxy cards submitted by mail must be received no later than May 17,September 6, 2023 to be voted at the AnnualSpecial Meeting.

During the Annual MeetingSpecial Meeting..    Instructions on how to vote while participating in the AnnualSpecial Meeting live via the Internet are posted at https://www.cstproxy.com/cepton/am2023.sm2023.

If you submit a proxy via the Internet or by telephone, your voting instructions authorize the proxy holders in the same manner as if you signed, dated and returned your proxy card. If you submit a proxy via the Internet or by telephone, you do not need to return your proxy card.

Can I revoke or change my vote after I submitted my proxy?

●      Can I revoke or change my vote after I submitted my proxy?

•        Beneficial Owners.    If you are a beneficial owner of your shares, you must contact the broker, bank or other nominee holding your shares and follow their instructions for revoking or changing your vote.

        Stockholders of Record.    If you are a stockholder of record, you may change or revoke a previously submitted proxy at any time before it is voted at the AnnualSpecial Meeting by:

        signing and returning a new proxy card with a later date;

        submitting a later-dated vote by telephone or via the Internet — only your latest Internet or telephone proxy received by 11:59 p.m., Eastern Time, on May 17,September 6, 2023, will be counted;

        participating in the AnnualSpecial Meeting live via the Internet and voting your shares electronically at the AnnualSpecial Meeting; or

        delivering a written revocation to our Corporate Secretary at the address above to be received before the voting at the AnnualSpecial Meeting.

How will my shares be voted if I do not provide specific voting instructions in the proxy I submit?

If you are a stockholder of record and you submit a signed proxy but do not indicate your specific voting instructions on one or more of the proposals listed in the Notice of AnnualSpecial Meeting of Stockholders accompanying this Proxy Statement, your shares will be voted as recommended by our Board on those proposals and as the proxy holders may determine in their discretion with respect to any other matters properly presented for a vote at the AnnualSpecial Meeting.

How many shares must be present or represented to conduct business at the Annual

How many shares must be present or represented to conduct business at the Special Meeting?

The holders of a majority of our shares of common stock issued and outstanding on the Record Date and entitled to vote at the AnnualSpecial Meeting, present or represented by proxy at the AnnualSpecial Meeting, will constitute a quorum for the transaction of business at the AnnualSpecial Meeting and any postponements or adjournments thereof. If you submit a proxy or voting instructions, your shares will be counted for purposes of determining the presence or absence of a quorum, even if you abstain from voting your shares. If a broker indicates on a proxy that it lacks discretionary authority to vote your shares on a particular matter, commonly referred to as “broker non-votes,” those shares will also be counted for purposes of determining the presence of a quorum at the AnnualSpecial Meeting. If a quorum is not present, our Bylaws provide that the AnnualSpecial Meeting may be adjourned by the chairperson of the meeting or by stockholders entitled to vote at the AnnualSpecial Meeting, present or represented by proxy.

CEPTON, INC.

2023 PROXY STATEMENT

35

QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND ANNUAL MEETING

What vote is required to approve each of the proposals?

Each share of our common stock outstanding at the close of business on the Record Date is entitled to one vote on each of the three director nomineesproposals and one vote on each other matter that may be presented for consideration and action by the stockholders at the AnnualSpecial Meeting.

20

Table of Contents

For purposeseach of Proposal 1 (election of directors), you may vote FOR ALL of the nominees, WITHHOLD your vote from all of the nominees or WITHHOLD your vote from any one of the nominees. Our Bylaws provide for a plurality voting standard for the election of directors. Under this voting standard, the three director nominees receiving the highest number of affirmative votes will be elected as Class A directors to serve until the 2026 annual meeting of stockholdersOne and until their respective successors are duly elected and qualified.

For purposes of Proposal 2 (ratification of the appointment of KPMG LLP as our independent registered public accounting firm),Two, you may vote FOR, AGAINST or ABSTAIN. Approval of this proposaleach of Proposal One and Proposal Two requires the affirmative vote of a majority of the voting power of the votes cast affirmatively or negativelywith respect to the respective proposal at the AnnualSpecial Meeting by the holdersstockholders of the Company present in person or represented by proxy and entitled to vote thereon.

Please be aware that Virtual attendance at our Special Meeting constitutes presence in person for the Special Meeting. If you hold your shares in “street name” (that is, your shares are held in an account at and registered in the name of a brokerage firm, bank, broker-dealer or similar organization), your broker or other organization may vote your shares under limited circumstances if you do not provide voting instructions before the Special Meeting. These circumstances include voting your shares on so-called “routine matters.” Each of Proposal 2One and Proposal Two is advisory onlya “routine” matter, and, is not bindingtherefore, no broker non-votes are anticipated on the Company. Our Board will consider the outcomeeither of the vote on this item in considering what action, if any, shouldmatters anticipated to be taken in response topresented at the advisory vote by stockholders.

What effect do withhold votes, abstentionsSpecial Meeting. Abstentions will not be treated as votes cast and broker non-votes have on the proposals?

For Proposal 1 (election of directors), shares voted “WITHHOLD” will not be counted in determining the outcome of a director nominee’s election. Forthe vote on either Proposal 2 (ratification ofOne or Proposal Two.

What effect do withhold votes, abstentions and broker non-votes have on the appointment of KPMG LLP as our independent registered public accounting firm), aproposals?

A vote to “ABSTAIN” with respect to the proposal isProposal One will not be treated as a vote cast and will not be counted in determining the outcome of Proposal One. A vote to “ABSTAIN” with respect to Proposal Two will not be treated as a vote cast and will not be counted in determining the vote on this proposal.outcome of Proposal Two.

If you are a beneficial stockholder that holds your shares through a brokerage account and you do not submit voting instructions to your broker, your broker may generally vote your shares in its discretion on routine matters. However, a broker cannot vote shares held for a beneficial stockholder on non-routine matters, unless the broker receives voting instructions from the beneficial stockholder. Both Proposal 2 (ratification of KPMG LLP as our independent registered public accounting firm) is considered routineOne and mayProposal Two are expected to be voted upon by your broker if you do not submit voting instructions. Proposal 1 (election of directors) is considered non-routine.“routine” matters.

Consequently, if you hold your shares through a brokerage account and do not submit voting instructions to your broker, your broker may exercise its discretion to vote your shares on Proposal 2 but will not be permitted to vote your shares onOne and Proposal 1. If your broker exercises this discretion, your shares will be voted on Proposal 2 in the manner directed by your broker, but your shares will constitute broker non-votes on Proposal 1 and will not be counted in determining the outcome of that item.Two.

Who will bear the costs of solicitation?

The accompanying proxy is being solicited on behalf of our Board. The cost of preparing, assembling, and mailing the Notice of AnnualSpecial Meeting of Stockholders, this Proxy Statement and form of proxy, and the 2022 Annual Report, the cost of making such materials available on the Internet and the cost of soliciting proxies and holding our virtual meeting of stockholders will be paid by us. In addition to the use of mail, we may solicit proxies in person or by telephone, facsimile or other means of communication by certain of our directors, officers and regular employees who will not receive any additional compensation for such solicitation. We will also reimburse brokers or other persons holding our common stock in their names or the names of their nominees for the expenses of forwarding soliciting material to their principals.

21

Table of Contents

APPENDIX A

CERTIFICATE OF AMENDMENT TO THE
SECOND AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
CEPTON, INC.1

Pursuant to the provisions of § 242 of the

General Corporation Law of the State of Delaware

Cepton, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows:

FIRST: Article IV, Paragraph (A) of the Corporation’s Second Amended and Restated Certificate of Incorporation is hereby amended to read in its entirety as follows:

“(A) Authorized Capital Stock.

The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is [            ]2 shares of capital stock, consisting of (i) [            ]3 shares of common stock, par value $0.00001 per share (the “Common Stock”), and (ii) five million (5,000,000) shares of preferred stock, par value $0.00001 per share (the “Preferred Stock”).

____________

1        Note: This Certificate of Amendment represents the form of each of the sixteen alternative potential amendments to the Second A&R Certificate. The alternative amendments are designated as amendments A through P, with each sequential amendment representing a ratio of one (1) share of common stock for each sequential whole number of issued shares of the Corporation’s common stock between five (5) and twenty (20)).

          Only one of the alternative amendments will be filed with the Secretary of State of the State of Delaware and therefore only one of such alternative amendments can become effective. All other alternative amendments will automatically be abandoned. The Board of Directors of the Corporation may also decide not to effect any of the alternative amendments, in which case all of the alternative amendments will be abandoned.

          The table below represents each of the alternative amendments and sets forth each possible reverse stock split ratio and the corresponding reduction in the total number of authorized shares of common stock and the total authorized number of shares that would be effected with respect to each such alternative amendment.

Column 1
Amendments

 

Column 2
Reverse Stock
Split Ratio
Range

 

Column 3
Number of Authorized
Shares of Common
Stock Following the
Reverse Stock Split and
Authorized
Shares Reduction

 

Column 4
Total Number of
Authorized Shares of
Stock Following the
Reverse Stock Split
and Authorized Shares
Reduction

A

 

1-for-5

 

70,000,000

 

75,000,000

B

 

1-for-6

 

60,000,000

 

65,000,000

C

 

1-for-7

 

50,000,000

 

55,000,000

D

 

1-for-8

 

45,000,000

 

50,000,000

E

 

1-for-9

 

40,000,000

 

45,000,000

F-G

 

1-for-10 to 1-for-11

 

35,000,000

 

40,000,000

H-I

 

1-for-12 to 1-for-13

 

30,000,000

 

35,000,000

J-K

 

1-for-14 to 1-for-15

 

25,000,000

 

30,000,000

L-M

 

1-for-16 to 1-for-17

 

22,500,000

 

27,500,000

N-O

 

1-for-18 to 1-for-19

 

20,000,000

 

25,000,000

P

 

1-for-20

 

17,500,000

 

22,500,000

2        Note: Refer to column 4 of the table in footnote 1 for the total number of authorized shares for each alternative amendment.

3        Note: Refer to column 3 of the table in footnote 1 for the number of authorized shares of the Corporation’s common stock for each alternative amendment.

A-1

Table of Contents

Upon the effectiveness of this Certificate of Amendment (the “Effective Time”), each [            ]4 shares of Common Stock, par value $0.00001 per share, issued and outstanding or held in treasury immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be reclassified and combined into one (1) validly issued, fully paid and non-assessable share of Common Stock, par value $0.00001 per share, of the Corporation (the “Reverse Stock Split”). No fractional shares shall be issued in connection with the Reverse Stock Split and, in lieu thereof, the fractional shares will be aggregated by the transfer agent and sold as soon as practicable after the Effective Time at the then-prevailing prices on the open market, on behalf of such holders who would have otherwise been entitled to receive a fractional share. Upon completion of such sale, stockholders who would have been entitled to a fractional share shall receive a cash payment (without interest) from the transfer agent in an amount equal to their respective pro rata share of the total proceeds of such sale net of any brokerage costs incurred by the transfer agent to sell such shares.

Notwithstanding anything to the contrary contained herein, the rights and preferences of the Common Stock shall at all times be subject to the rights and preferences of the Preferred Stock as may be set forth in the Certificate of Incorporation or one or more certificates of designations filed with the Secretary of State of the State of Delaware from time to time in accordance with the DGCL and this Certificate of Incorporation. The number of authorized shares of Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) from time to time by the affirmative vote of the holders of at least a majority of the voting power of the Corporation’s then outstanding shares of capital stock entitled to vote thereon, voting together as a single class, irrespective of the provisions of Section 242(b)(2) of the DGCL (or any successor provision thereto), and no vote of the holders of the Common Stock or the Preferred Stock voting separately as a class or series shall be required therefor unless a vote of any such holder is required pursuant to this Certificate of Incorporation (including any certificate of designation relating to any series of Preferred Stock).”

SECOND: The foregoing amendment was duly adopted in accordance with Section 242 of the DGCL.

THIRD: This Certificate of Amendment shall be effective at [    ] p.m. Eastern Time on [            ], 2023.

* * * * *

____________

4        Note: Refer to column 2 of the table in footnote 1. Each sequential amendment represents a ratio of one (1) share of common stock for each sequential whole number of issued shares of the Corporation’s common stock between five (5) and twenty (20).

A-2

Table of Contents

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by its duly authorized officer on this [            ] day of [            ] 2023.

36By:

 

2023 PROXY STATEMENT/s/ Jun Pei

Name:

 

CEPTON, INC.Jun Pei

Title:

President and Chief Executive Officer

A-3

Table of Contents

YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet or Telephone - QUICK EASY IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail CEPTON, INC. Your phone or Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet or by telephone must be received by 11:59 p.m., Eastern Time, on May 17,September 6, 2023. INTERNET/MOBILEINTERNET – www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. Vote at the Meeting – If you plan to attend the virtual online Annual Meseting,special meeting, you will need your 12 digit control number to vote electronically at the Annual Meeting.special meeting. To attend;attend: https://www.cstproxy.com/cepton/am2023 PHONE – 1 (866) 894-0536 Use a touch-tone telephone to vote your proxy. Have your proxy card available when you call. Follow the voting instructions to vote your shares.SM2023 MAIL – Mark, sign and date your proxy card and return it in the postage-paid envelope provided. PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING ELECTRONICALLY OR BY PHONE.ELECTRONICALLY. FOLD HERE • DO NOT SEPARATE • INSERT IN ENVELOPE PROVIDED PROXY CARD THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR ALL” DIRECTOR NOMINEES NAMED IN PROPOSAL“FOR” PROPOSALS 1 AND “FOR” PROPOSAL 2. Proposal One Approve a series of sixteen alternative potential amendments to the Company’s Second Amended and Restated Certificate of Incorporation to authorize the Company’s Board of Directors to effect (i) a reverse stock split of the issued shares of our common stock (including shares of common stock held by the Company in treasury), at ratios of 1 share of common stock for each whole number of issued shares of our common stock between five and twenty, which ratio to become effective to be determined by the Board of Directors if the Board of Directors subsequently determines to proceed with the reverse stock split, and (ii) a corresponding reduction in the total number of authorized shares of common stock and corresponding reduction in the total number of shares the Company is authorized to issue. FOR AGAINST ABSTAIN Please mark your votes like this 1. PROPOSAL 1 — ELECTION OF DIRECTORS Election of three Class A directorsProposal Two Adjourn the Special Meeting, if necessary or appropriate, to serve until the Company’s 2026 annual meeting of stockholders and until their respective successorssolicit additional proxies if there are duly elected and qualified Nominees: 01) Dr. Jun Ye 02) Dr. Mei (May) Wang 03) Mr. Hideharu (Harry) Konagaya FOR ALL FOR All WITHHOLD EXCEPT To withhold authorityinsufficient votes to vote for any individual nominee(s), mark “For All Except” and write the number(s) of the nominee(s) on the line below. 2. PROPOSAL 2 — RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL 2023approve Proposal One. FOR AGAINST ABSTAIN NOTE: If any other matters properly come before the meeting, unless such authority is withheld on this proxy card, the proxies will vote on such matters in their discretion. CONTROL NUMBER Signature______________________________Signature,Signature Signature, if held jointly__________________________________ Date_____________,jointly Date, 2023 Note: Please sign exactly as name appears hereon. When sharesShares are held by joint owners,tenants, both should sign. When signing as attorney, executor, administrator, trustee guardian, or corporate officer,guardian, please give full title as such. If signing as a corporation, or partnership, please sign in full corporate name by president or other authorized officer. If a partnership, please sign in partnership name by an authorized officerperson.

 

Table of Contents

FOLD HERE DO NOT SEPARATE INSERT IN ENVELOPE PROVIDED PROXY CARD FOR SPECIAL MEETING OF STOCKHOLDERS OF CEPTON, INC. THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints each of Jun Pei and Hull Xu or either of them, with full power of substitution,(each, a “Proxy”) as proxy, ofwith the power to appoint a substitute to vote the shares that the undersigned is entitled to attendvote (the “Shares”) at the annual meetingSpecial Meeting of stockholders (the “Annual Meeting”) of Cepton, Inc., to be held via live web cast as described in the Proxy Statement on May 18,September 7, 2023 at 9:00 a.m. Pacific time,Time, virtually via live webcast at https://www.cstproxy.com/cepton/SM2023 or at any adjournments and/ or postponements thereof. Such Shares shall be voted as indicated with respect to the proposals listed on the reverse side hereof and in the Proxy’s discretion on such other matters as may properly come before the Special Meeting or any adjournment or postponement or adjournment thereof, and to vote as if the undersigned were then and there present:thereof. The undersigned acknowledges receipt of the accompanying proxy statement, and revokes all prior proxies for said meeting. THE SHARES REPRESENTED BY THETHIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER(S).SHAREHOLDER. IF NO SPECIFIC DIRECTION IS MADE,GIVEN AS TO THE PROPOSALS ON THE REVERSE SIDE, THIS PROXY WILL BE VOTED “FOR ALL” DIRECTOR NOMINEES NAMED INFOR EACH OF PROPOSAL 1 AND “FOR” PROPOSAL 2. PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY. IF ANY OTHER MATTERS PROPERLY COME BEFORE THE MEETING, UNLESS SUCH AUTHORITY IS WITHHELD ON THIS PROXY CARD, THE PROXIES WILL VOTE ON SUCH MATTERS IN THEIR DISCRETION. PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY.PROMPTLY (Continued and to be marked, dated and signed on the otherreverse side)